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2801-3 Single Antiplatelet Therapy With Clopidogrel Is Safe 
After Drug-Eluting Stent Implantation in Patients on 
Anticoagulants
Vincenzo Pasceri, Giuseppe Patti, Francesco Pelliccia, Christian Pristipino, Adriana 
Roncella, Diego Irini, Giulio Speciale, Germano Di Sciascio, San Filippo Neri Hospital, 
Rome, Italy, Campus Bio-medico University, Rome, Italy
Background: Current guidelines require at least one year of double antiplatelet therapy 
(aspirin + clopidogrel) after drug-eluting stent (DES) implantation. However, the optimal 
treatment of patients requiring also chronic anticoagulation remains unclear, since use 
of double antiplatelet therapy on top of anticoagulation is associated with increased risk 
of bleeding.
Methods: We tested the safety and efficacy of a strategy using chronic clopidogrel 
therapy + anticoagulation in 54 consecutive patients (age 66±9 years, 31% with diabetes) 
receiving DES; most patients (81%) had permanent atrial fibrillation. All patients received 
aspirin+clopidogrel at the time of angioplasty and for the first week, then aspirin was 
stopped and clopidogrel was continued for at least one year. Results: Patients recieved 
an average of 1.6 stents/pt (24% with multivessel stenting), with 54% sirolimus eluting 
stents, 46% taxol eluting stents. At 1 year follow-up there were no cases of definite or 
probable stent thrombosis, 2 cases of myocardial infarction (with disease progression 
on different vessels) and 4 cases of target vessel revascularization. There were no 
hemorragic complications requiring transfusion; two patients had gastrointestinal bleeding 
requiring discontinuation of clopidogrel.
Conclusions: A strategy of long term treatment with clopidogrel only after DES seems 
safe for patients requiring chronic anticoagulation 
1:15 p.m.
2801-4 Drug-eluting Stents for ST Elevation Myocardial 
Infarction: Evidence for Benefit at Two Years
Sanjay K. Gandhi, James D. Kay, Robert J. Applegate, Matthew T. Sacrinty, Michael A. 
Kutcher, Renato M. Santos, William C. Little, Wake Forest University School of Medicine, 
Winston-Salem, NC
Background. Percutaneous coronary intervention (PCI) is associated with lower mortality 
in patients presenting with ST elevation myocardial infarction (STEMI). Although PCI with 
coronary stenting is a standard therapy for STEMI, recent trial data suggest that the use of 
drug eluting stents (DES) for STEMI is associated with worse outcomes in comparison to 
bare metal stents (BMS). Whether DES for STEMI in routine clinical practice is associated 
with worse outcomes than BMS is uncertain.
Methods. Clinical outcomes were reviewed for all patients hospitalized at Wake Forest 
University Baptist Medical Center for STEMI from 4/02 to 4/05 who underwent PCI within 
24 hours. BMS were implanted in 252 patients and DES were implanted in 257 patients. 
Two year follow-up was 82% in the BMS group and 85% in the DES group (p=0.292).
Results. For use of DES compared to BMS, hazard ratios were 0.35 (0.14-0.83) for target 
vessel revascularization (TVR) at 2 years, 0.42 (0.14-1.20) for stent thrombosis, 0.55 (0.33-
0.92) for all cause mortality, and 0.49 (0.32-0.77) for non-fatal MI or death (95% confidence 
intervals). The Kaplan-Meier plot for non-fatal MI or death is shown in the figure.
Conclusions. DES in PCI for STEMI was associated with better 2 year outcomes than 
BMS in this real world single-center experience. Use of DES for STEMI may convey a long-
term benefit in reduction of TVR, non-fatal MI or death, and mortality compared to BMS.
1:30 p.m.
2801-5 Impact of clopidogrel loading dose on the safety and 
effectiveness of bivalirudin in patients undergoing 
primary angioplasty for acute myocardial infarction: 
The HORIZONS AMI Trial
George Dangas, Giulio Guagliumi, Bernhard Witzenbichler, Deepak Bhatt, Frederick 
Feit, Magnus Ohman, S. Chiu Wong, Helen Parise, Roxana Mehran, Gregg W. Stone, 
Columbia University Medical Center/Cardiovascular Research Foundation, New York
Background. In the HORIZONS AMI trial, bivalirudin monotherapy (Biv) compared to 
unfractionated heparin (UFH) plus glycoprotein IIb/IIIa inhibitors (GPI) resulted in reduced 
30 day rates of major bleeding, comparable composite major adverse cardiovascular 
events (MACE) (although with decreased cardiac mortality), and enhanced freedom from 
net adverse clinical events (NACE) in pts with AMI undergoing primary PCI. All pts were to 
receive a clopiodgrel loading dose in the ER, either 300 mg or 600 mg, and randomization 
was stratified by this decision. Whether the beneficial effects of Biv are independent of the 
clopidogrel loading dose has not been reported.
Methods and Results. A total of 3602 pts at 123 centers in 11 countries with AMI undergoing 
primary PCI were randomized to Biv (n=1800) vs. UFH+GPI (n=1802). Randomization was 
stratified by clopidogrel loading dose: n=1,248 in the 300mg stratum and n=2,349 in the 
600mg stratum. In the entire study population, Biv compared to UFH+GPI resulted in a 
40% reduction in major bleeding (4.9% vs. 8.3%, P<0.0001), similar MACE (5.4% vs. 5.5%, 
P=1.0), and a 24% reduction in NACE (9.2% vs. 12.1%, P=0.006). As shown in the table, 
the impact of Biv was independent of the clopidogrel loading dose (interaction p values for 
the above 3 endpoints = 0.41, 0.75, and 0.48 respectively).
Conclusions. In patients with AMI undergoing primary PCI, Biv monotherapy significantly 
reduces major bleeding and net adverse clinical events, independent of the clopidogrel 
loading dose. 
Clopidogrel 300mg (n=1248) Clopidogrel 600mg (n=2349)
Biv UFH+GPI RR [95%CI] Biv UFH+GPI RR [95%CI]
Major bleeding 6.5% 9.6% 0.68 [0.46-0.99] 4.1% 7.6% 0.54 [0.38-0.76]
MACE* 7.0% 6.8% 1.04 [0.69- 1.57] 4.5% 4.8% 0.95 [0.66- 1.37]
NACE** 12.0% 14.5% 0.83 [0.62- 1.10] 7.7% 10.8% 0.71 [0.55- 0.92]
* MACE = death, reinfarction, ischemic TVR or stroke;
**NACE (Net Adverse Clinical Events) = MACE or major bleeding
1:45 p.m.
2801-6 Assessment of Platelet Function With Light 
Transmission Aggregometry and Multiple Electrode 
Platelet Aggregometry Before and After Clopidogrel 
Treatment
Dirk Sibbing, Siegmund Braun, Stefan Jawansky, Wolfgang Vogt, Julinda Mehilli, Julia 
Ellert, Albert Schomig, Adnan Kastrati, Nicolas von Beckerath, Deutsches Herzzentrum 
Muenchen, Muenchen, Germany
Background: The level of platelet aggregation, measured with light transmission 
aggregometry (LTA), has been shown to predict outcomes after PCI. However, measuring 
platelet function with LTA is time consuming and weakly standardized. Thus, a fast and 
standardized method to assess platelet function after clopidogrel treatment would be of 
great value for clinical practice. A new method, multiple electrode platelet aggregometry 
(MEA), to rapidly measure platelet aggregation in whole blood has been developed 
recently. The aim of this study was to assess platelet function with MEA and LTA before 
and after administration of 600 mg clopidogrel.
Methods: Blood samples from 149 patients scheduled for coronary angiography were 
taken after clopidogrel treatment; in addition, in 60 of the patients samples were available 
before clopidogrel treatment. Adenosine diphosphate (ADP)-induced platelet aggregation 
was measured with LTA and simultaneously in whole blood with MEA on the Multiplate 
analyzer. Aggregation measured with MEA is quantified as area under the curve 
(AUC=AU*min) of arbitrary units (AU).
Results: Platelet aggregation measured with MEA decreased significantly after 
clopidogrel treatment (Figure A). The correlation of all available values from all patients 
(n=149) obtained with LTA and with MEA before and after administration of clopidogrel 
was highly significant (Spearman rank correlation coefficient=0.71) (Figure B).
Conclusions: MEA is a fast and standardized method to individually assess platelet 
function prior to and after clopidogrel treatment. Its results correlate with those of LTA. 
MEA may be helpful in tailoring antiplatelet regimes in patients scheduled for PCI. 
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2801-7 Triple Versus Dual Antiplatelet Therapy in Patients With 
Acute Myocardial Infarction Undergoing Percutaneous 
Coronary Intervention
Kang-yin Chen, Seung-Woon Rha, Zhe Jin, Yoshiyasu Minami, Jin Oh Na, Cheol Ung 
Choi, Soon Yong Suh, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, 
Dong Joo Oh, Myung Ho Jeong*, Cardiovascular Center, Korea University Guro Hospital, 
Seoul, South Korea, Cheon Nam National University Hospital*, GwangJu, South Korea
Background: Whether the safety and efficacy of triple antiplatelet strategy is superior or 
similar to the dual antiplatelet strategy in patients (pts) with acute myocardial infarction 
(AMI) undergoing percutaneous coronary intervention (PCI) is still unclear. 
Methods: A total of 4,892 AMI pts undergoing PCI were randomly assigned to receive 
either dual antiplatelet therapy (aspirin plus clopidogrel, Dual group, n=2,974) or triple 
antiplatelet therapy (aspirin plus clopidogrel plus cilostazol, Triple group, n=1,918). All 
major adverse cardiac events (All MACE) included total death, revascularization, and 
myocardial re-infarction. The bleeding complications and clinical outcomes of in-hospital, 
1 and 6 months were compared between the two groups.
Results: The baseline characteristics were similar between the two groups. The early 
mortality and revascularization rate were lower in Triple group up to one month and 
all MACE was significantly lower up to 6 months. Interestingly, Triple group also had a 
significantly lower in-hospital major bleeding (Table). This result might be due to the Triple 
group had less history of peptic ulcer disease (0.4% vs. 0.9%, P=0.034).
Conclusions: Triple antiplatelet therapy appears to be superior in preventing the MACE 
without increasing the major bleeding events in pts with AMI undergoing PCI compared 
with the conventional dual antiplatelet therapy.
Table: Clinical outcomes of study population 
Variable, n (%) Dual group(n=2,974 pts)
Triple group
(n= 1,918 pts) P value
In-hospital
Total death 89 (3.0) 34 (1.8) 0.008
Reinfarction 12 (0.4) 9 (0.5) 0.730
Revascularization 41 (1.4) 12 (0.6) 0.013
All MACE 142 (4.8) 55 (2.9) 0.001
TIMI-major bleeding 12 (0.6) 3 (0.2) 0.023
At 1 month
Total death 106 (3.7) 50 (2.7) 0.046
Reinfarction 25 (0.9) 10 (0.5) 0.175
Revascularization 71 (2.5) 26 (1.4) 0.008
All MACE 202 (7.1) 86 (4.6) 0.001
At 6 months
Total death 124 (4.3) 65 (3.5) 0.147
Reinfarction 34 (1.2) 13 (0.7) 0.097
Revascularization 150 (5.2) 75 (4.0) 0.055
All MACE 308 (10.7) 153 (8.2) 0.004
2:15 p.m.
2801-8 Questions and Answers
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2901 
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1:00 p.m.
2901-5 Long-term Clinical Outcome of Sirolimus-eluting Stent 
Implantation in Bifurcation Lesions from The j-Cypher 
Registry: Comparison of Simple Versus Complex 
Stenting Techniques
Toshihiro Tamura, Kazuaki Mitsudo, Takeshi Kimura, Takeshi Morimoto, Kazushige 
Kadota, Yoshiharu Murata, Makoto Muto, Natsuki Nakamura, Hitoshi Nakashima, 
Masanobu Namura, Hideo Nishikawa, Masakiyo Nobuyoshi, Masanori Nomura, Yoichi 
Nozaki, Shigeru Ohshima, Shigeru Saito, Keijiro Saku, Yoshisato Shibata, Nobuo 
Shiode, Takahito Sone, Shunsuke Take, Masaru Tanaka, Ryozo Tatami, Shinichiro 
Toyoshima, Yoshiaki Yokoi, Kyoto University Hospital, Kyoto, Japan
Background:Although various approaches using Sirolimus-eluting stents(SES) in 
coronary bifurcations have been proposed, bifurcation treatment with stent implantation 
still raise controversy.
Methods:Design of the j-Cypher Registry was multi-center prospective enrollment of 
consecutive patients receiving SES from 41 centers in Japan. As of July 31, 2007, long-
term follow-up data were available in 10521 patients underwent successful implantation 
of SES. Among them, we identified 1736 patients(1854 lesions) who were treated with 
SES in bifurcation lesions excluding left main coronary artery, left anterior descending 
artery ostium and left circumflex coronary artery ostium. 1596 lesions were treated 
with stenting of the main vessel and provisional stenting of the side branch and 258 
lesions were treated with elective stenting of the main vessel and side branch. We 
divided into simple technique( finally stenting only main vessel: group S) and complex 
technique(finally stenting main vessel and side branch: group C). Two strategies were 
selected according to the operators’ discretion. We compared long-term(follow-up period 
was 462.6±222.7days) clinical outcome of both strategies.
Results:783 lesions(43.4%) were true bifurcations. Only 96 lesions(6.0%) among those 
which were treated with provisional stenting of the side branch crossed to the group C 
and no lesion crossed to group S from elective two stenting. 1395 patients(1500 lesions) 
were included in group S and 341 patients(354 lesions) in group C. 4 methods of two 
stenting were used: T-stenting(57.3%), Culotte stenting(20.1%), Crush stenting(19.8%), 
and V stenting(2.8%). There was no significant differences between group S and group C 
in myocardial infarction(1.9% vs 2.1%,p=0.82) and all stent thrombosis(0.43% vs 0.88%, 
p=0.33) at long-term. However the incidence of target lesion revascularization(12.0% vs 
5.4%,p<0.0001) and cumulative major adverse cardiac events(19.4% vs 10.5%,p<0.0001) 
were significantly higher in group C than in group S.
Conclusions:For SES placement in bifurcation lesions, one stent technique suggests a 
good long-term outcome compared with two stent technique regarding TLR and MACE.
1:06 p.m.
2901-6 Stent Fracture and Clinical Outcomes in the TAXUS and 
ATLAS Trials
Jeffrey J. Popma, Alexandra Almonacid, Lazar Mandinov, Dominic J. Allocco, Donald S. 
Baim, Brigham And Women’s Hospital, Boston, MA
Background: Stent fracture (SF) incidence at 8 months has been reported in 2.6% 
of closed-cell stent designs (Aoki et al. Catheter Cardiovasc Interv 2007; 69:380-386) 
with 50% of such fractures associated with clinical restenosis. Few data are available 
regarding SF rates with open-cell designs. This analysis evaluated the incidence and 
consequences of SF in >2,400 patients from the TAXUS clinical trial program (Express® 
stent platform) and the ATLAS trial (Liberté™ stent platform). Whereas TAXUS IV and 
ATLAS enrolled patients with relatively uncomplicated lesions, TAXUS V and VI enrolled 
patients with more complex lesions (eg, smaller vessels, longer lesions, and overlapping 
stents) in whom the rate of SF may be increased.
Methods: Angiograms from the TAXUS IV, V, VI and ATLAS clinical trials were 
retrospectively reviewed by an independent angiographic core laboratory. The incidence 
of SF in the subset assigned to 9 month follow-up angiography provided an estimate of 
SF. All other available late angiograms were also reviewed to evaluate any association 
between SF and adverse events.
Results: The observed incidence of stent fracture at 9 month protocol-driven angiography 
was 0% (0/600 stents) in TAXUS IV, 0.8% (11/1338 stents) in TAXUS V, 0.3% (2/581 
stents) in TAXUS VI, and 0% (0/541 stents) in ATLAS. Over the entire length of follow-up 
(N=2,814 patients; 3,060 stents), 4 additional SFs were identified (2 in TAXUS IV at 525 
and 1,668 days, 1 in TAXUS V at 716 days and 1 in ATLAS at 778 days). SF was more 
common in complex lesions, with 10/17 total SFs occurring in overlapping stents. Over 
the entire course of clinical follow-up (median=1,446 days), there were 137 deaths, 494 
TLRs, 197 MIs, and 38 stent thromboses (ARC definite+probable). No deaths, 4 (0.8%) 
TLRs, 3 (1.5%) MIs, and 2 (5.3%) stent thromboses were associated with an underlying 
stent fracture.
Conclusions: Stent fracture is very rare with Express (13 of 2,519=0.5%) and Liberté (0 
of 541=0%) at the time of routine angiographic follow-up, is mostly confined to overlapping 
stents and complex lesions. Stent fracture was not a significant cause of adverse events 
in the TAXUS and ATLAS trials.
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2901-7 There Is No Increased Risk of Death Following 
Placement of a Drug-eluting Stent in a Saphenous Vein 
Graft
Kelly R. O’Neal, III, David M. Safley, Kevin F. Kennedy, John A. House, James A. Grantham, 
Barry D. Rutherford, Steven P. Marso, Mid America Heart Institute, Kansas City, MO
Background: Placement of a drug eluting stent (DES) in a saphenous vein graft 
(SVG) is an off-label use. Few data compare DES with bare metal stents (BMS) in SVG 
percutaneous coronary interventions (PCI), and recent data suggests increased mortality 
with DES in SVG. The objective of this study was to examine mortality in these two groups 
in a real-world registry.
Methods: We identified 251 consecutive patients in the Mid America Heart Institute 
procedural database that had SVG PCI between January 1, 2003 and December 31, 
2006. We assessed mortality via the Social Security Death Master File. Adjusted Kaplan-
Meier analysis was used to compare survival between groups.
Results: BMS were placed in 120 patients and DES in 131. There was no difference 
in age, gender, ejection fraction, hypertension, hypercholesterolemia, renal failure 
or diabetes between the groups. More smokers received a BMS (43% vs. 26% DES, 
p=0.006). The average number of stents per patient was similar (1.5±0.9 BMS, 1.5±0.9 
DES, p=0.53), as was single-vessel PCI (70% BMS, 67% DES, p=0.86). Mean follow-up 
was 2.4 years. The difference in mortality was non-significant following adjustment for 
age, gender and diabetes (p = 0.45).
Conclusions: This single center “real-world” experience suggests there is no increased 
death following SVG PCI with DES compared with BMS. In fact, there was a numerical 
excess of deaths in the BMS group. Further study in a large randomized trial is 
warranted.
1:18 p.m.
2901-8 Mid- to Long-term Survival in Patients With Left 
Ventricular Dysfunction Undergoing Sirolimus- or 
Paclitaxel-eluting Stent Implantation
Annunziata Nusca, Michael J. Lipinski, Amit Varma, Darryn L. Appleton, Evelyne Goudreau, 
Michael J. Cowley, Michael Wittkamp, Germano Di Sciascio, Antonio Abbate, George W. 
Vetrovec, Virginia Commonweath University Pauley Heart Center, Richmond, VA
Background: Recent data has shown a potential increase in mortality associated 
with DES possibly due to late stent thrombosis (LST). Left ventricular (LV) 
dysfunction is considered a risk factor for LST. Aim of the current study was 
to assess mid- to long-term survival rates in high risk patients with LV systolic 
dysfunction undergoing drug-eluting stent implantation.
Methods: Patients with an ejection fraction <45% undergoing PCI between April 
2003 and December 2005 who had at least one sirolimus- or paclitaxel-eluting stent 
placed were selected for screening. As historical control patients treated with bare-
metal stents prior to the introduction of DES between May 1996 and March 1999 
were studied. Mortality rates were retrieved from the Social Security database.
Results: . One hundred twenty three patients who received at least one DES were 
selected for inclusion in the study, and compared with 113 historical control 
patients treated with BMS. Survival at 1-, 2- and 3-year follow up was 95%, 90% and 
86% for patient who received a DES, respectively (see Figure). 
Conclusions: The favorable survival data with DES in patients with left ventricular 
dysfunction is reassuring and within the limitations of a retrospective analysis 
suggests added benefit of DES (vs BMS) in a higher risk cohort such as those with 
LV dysfunction, without showing any signal of late mortality hazard. 
1:24 p.m.
2901-9 Correlation of Intravascular Ultrasound Findings With 
Histopathologic Analysis of Thrombus Aspirates in 
Patients With Very Late DES Stent Thrombosis
Stephane Cook, Elena Ladich, Parham Eshtehardi, Rolf Vogel, Mario Togni, Michael 
Billinger, Peter Wenaweser, Christian Seiler, Otto M. Hess, Bernhard Meier, Renu 
Virmani, Stephan Windecker, Swiss Cardiovascular Center, Bern, Bern, Switzerland
Background and Purpose: Necropsy studies of patients with late drug-eluting stents 
(DES) thrombosis showed evidence of delayed healing and hypersensitivity reactions. 
Intravascular ultrasound (IVUS) studies of patients with late stent thrombosis (ST) 
revealed positive vessel remodelling and incomplete stent apposition. The purpose of the 
present study was to correlate IVUS findings with histopathologic analysis of thrombus 
aspirates in patients with very late DES thrombosis (>1 year).
Methods and Results: IVUS and thrombus aspiration were systematically performed 
in patients with very late ST undergoing emergency percutaneous coronary intervention 
(PCI). IVUS was performed prior to PCI in the ST-segment (40% LAD, 20% RCX, 40% 
RCA) using motorized pullback (0.5 mm/s). Thrombus was harvested from the ST segment 
with an aspiration catheter prior to PCI and sent for detailed histopathological analysis. 
The study population consisted of 9 patients (age 60±12 years) with 10 thrombosed 
stent segments (4 SES, 5 PES, 1 ZES; total stent length 29.2±20.2 mm) presenting 
1007±248 days after DES-implantation. Incomplete stent apposition (ISA) was present 
in 70% of cases with an ISA-CSA of 6.1±1.6mm2 and evidence of vessel remodelling 
(EEM reference area: 13.3±2.6mm2 vs. EEM in-stent area: 20.1±3.9mm2, p<0.0001). 
Histopathologic analysis showed fresh thrombus with intense inflammatory infiltrates in 
all aspirates. Eosinophilic infiltrates were present in patients with large ISA (> 4 mm2), 
whereas neutrophilic infiltrates were associated with small or absent ISA.
Conclusion. Very late DES ST is associated with histopathologic evidence of chronic 
inflammation and IVUS evidence of vessel remodelling. The presence of eosinophils 
suggest a hypersensitivity reaction as likely cause of vessel remodelling and thus very 
late ST in selected patients.
1:30 p.m.
2901-10 Impact of Drug-eluting Versus Bare Metal Stents on 
Long-term Mortality in Real World Clinical Practice
Dmitriy N. Feldman, Christopher L. Gade, Geoffrey Bergman, Nichole Polin, Robert 
M. Minutello, S. Chiu Wong, New York Presbyterian Hospital - Weill Medical College of 
Cornell University, New York, NY
Background: Recent head-to-head trials comparing drug-eluting stents (DES) and bare 
metal stents (BMS) reported a lower restenosis rate with DES and similar intermediate-
term mortality rates. Given potential increase in very late (>1 year) thrombosis of DES, 
clinical outcomes after implantation of DES versus BMS need to be examined in “real 
life” practice.
Methods: Using the 2004/2005 Cornell Angioplasty Registry, we studied 2,362 
consecutive patients undergoing urgent or elective PCI. Mean follow-up was 24.8 ± 7.6 
months.
Results: Of the 2,362 study patients, 2,174 (92.0%) underwent DES implantation and 
188 (8.0%) received BMS. Multilesion (50.5% vs. 33.5%, p<0.001) and multivessel PCI 
(16.2% vs. 5.9%, p<0.001) was performed more frequently in DES vs. BMS groups, 
respectively. The incidence of in-hospital post-procedural MI (7.2% vs. 9.6%, p=0.243) 
and MACE including death, stroke, emergent CABG/PCI, and MI (7.3% vs. 10.6%, 
p=0.112) were similar in both DES and BMS groups. However, DES patients had lower 
in-hospital mortality (0.1% vs. 1.1%, p=0.054). During the follow-up period, there were 87 
(4.0%) deaths in the DES group vs. 26 (13.8%) deaths in the BMS group (HR 0.3, 95%CI 
0.2-0.4, p<0.001) (Figure). After multivariate Cox analysis, DES use was associated with 
improved long-term survival (HR 0.4, 95%CI 0.2-0.7, p=0.001).
Conclusions: DES use in comparison with BMS is associated with improved in-hospital 
and long-term survival in real world practice. Despite a small increase in very late stent 
thrombosis observed in randomized, multicenter trials involving selective patient cohorts, 
DES use is associated with improved long-term survival in “real life” practice. 
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2901-11 Inflammation and Vulnerability of Culprit Lesion May 
Promote Neointimal Coverage After Sirolimus-eluting 
Stent Implantation
Masami Nishino, Shinpei Nakatani, Masahiko Hara, Akihito Hashimoto, Kiyoshi 
Yamagami, Ken Matsuoka, Hiroyasu Kato, Yasuyuki Egami, Ryu Shutta, Hitoshi 
Yamaguchi, Kenjiro Tanaka, Jun Tanouchi, Yoshio Yamada, Osaka Rosai Hospital, Sakai, 
Osaka, Japan
Background: Neointimal formation can protect thrombosis after sirolimus-eluting stent 
(SES) implantation, however promoters of neointimal formation after SES implantation 
are unknown. In this study we examined which parameters promote neointimal formation 
after SES implantation using coronary angioscope (CAS).
Methods: Six-month follow-up CAS was performed in 141 consecutive patients with SES 
implantation. All patients received aspirin (100mg) and ticlopidine (200mg) until CAS. We 
defined three grades of neointimal coverage as follows: 0: no neointimal coverage of stent 
struts, 1: partial coverage, 2: complete coverage. The possible promoters of neointimal 
formation that were evaluated in this study were as follow: vulnerability of culprit lesion 
(stable angina or acute myocardial infarction), CAS parameters including existence of 
visible thrombus and plaque color around stent (white or yellow), and serum parameters 
including low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, 
hemoglobin A1c, high sensitive C-reactive protein (hs-CRP) and fibrinogen.
Results: Simple regression analyses revealed that the grade of neointimal coverage 
was significantly correlated with hs-CRP, plaque color and vulnerability of lesion, while 
there were no significant correlations between the grade of neointimal coverage and the 
other parameters including angioscopic visible thrombus. Multiple regression analysis 
using these three parameters revealed higher hs-CRP and acute myocardial infarction 
significantly promoted neointimal coverage (table).
Conclusions: Inflammation and vulnerability of culprit lesion may induce neointimal 
coverage after SES implantation. This phenomenon may support the safety of SES for 
acute myocardial infarction.
Promoters of Neointimal Coverage
Regression coefficient p Value
Plaque color 0.08 0.482
Acute myocardial infarction 0.36 0.002
hs-CRP 0.29 0.010
1:42 p.m.
2901-12 Incidence and Short-term Outcomes of Drug-eluting 
Stent Fracture in Chronic Total Occlusions: Analysis 
From the ACROSS-Cypher Trial
Sunil V. Rao, David E. Kandzari, Kelley A. Ryan, Jyotsna Garg, Christopher E. Buller, 
Bradley H. Strauss, Michael J. Kutryk, Jeffrey W. Moses, Vladimir Dzavik, G.B. John 
Mancini, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
Background: Incidence, predictors, and clinical correlates associated with coronary stent 
fracture (SF) in complex percutaneous revascularization are not well understood.
Methods: In a prospective study of 200 consecutive chronic total occlusion (CTO) pts 
(76% >6 weeks CTO age) with sirolimus-eluting stents (SES), baseline and 6-month 
f/u angiograms were independently reviewed by 2 physicians for SF and adjudicated 
by consensus. Primary endpoint was 6-month angiographic binary restenosis (>=50% 
stenosis) assessed by an independent core lab (88% angiographic f/u).
Results: Of 200 pts (451 SES, mean stent length 56.4 mm), 56 SF (44 definite, 12 
possible) were found in 32 pts (16%) at 6-month f/u. Definite SF characteristics: 86% 
right coronary artery (RCA); 23% >45° angulation; 14% in regions of extreme dynamic 
motion; 41% localized to stent body; and 59% in or adjacent to overlapping stents. Six-
month MACE in SF and non-SF pts did not significantly differ (9.4% SF vs. 6.1% non-SF, 
P=0.45). Angiographic characteristics and adjudicated 6-month clinical outcomes are 
compared.
Conclusion: In pts with SES in complex CTOs, SF was associated with an RCA location, 
overlapping stents, and significant vessel angulation or extreme torque/motion. Despite 
numerically higher restenosis, SF was not associated with significantly higher repeat 
target lesion revascularization, stent thrombosis, or MACE. Planned 5-year f/u will provide 
more data on long-term consequences of SF related to DES treatment in CTOs.
*Death, any MI, CABG, TLR.
Stent Fracture Pts
(N=32)
Non-stent Fracture Pts
(N=168) P
Stent length, mean (SD), mm 69.7 (24.6) 45.0 (22.2) <0.001
Overlapping stents, n/N (%) 30/30 (100.0) 107/119 (89.9) 0.06
Procedure success, n/N (%) 30/32 (93.8) 147/167 (88.0) 0.54
TLR, n/N (%) 3/32 (9.4) 9/165 (5.5) 0.42
MACE*, n/N (%) 3/32 (9.4) 10/165 (6.1) 0.45
Stent thrombosis, n/N (%) 1/32 (3.1) 0/165 (0.0) 0.16
Binary restenosis, n/N (%)
In-segment 7/32 (21.9) 16/137 (11.7) 0.07
In-stent 5/32 (15.6) 10/136 (7.4) 0.09
1:48 p.m.
2901-13 Clinical and Angiographic Outcomes With Sirolimus-
eluting Stents in Total Coronary Occlusions: ACROSS/
TOSCA-4 Trial
David E. Kandzari, Sunil V. Rao, Jeffrey W. Moses, Vladimir Dzavik, Bradley H. 
Strauss, Michael J. Kutryk, Charles A. Simonton, III, Jyotsna Garg, G.B. John Mancini, 
Christopher E. Buller, Duke Clinical Research Institute, Duke University Medical Center, 
Durham, NC
Background: Despite evaluation of drug-eluting stents (DES) beyond approved 
indications, few studies have evaluated the clinical benefit of DES in chronic total coronary 
occlusion (CTO) revascularization. The ACROSS-Cypher/TOSCA 4 study is a prospective 
multicenter non-randomized trial examining the safety and efficacy of sirolimus-eluting 
stents (SES) in percutaneous CTO revascularization.
Methods: Among 15 centers in North America, 200 consecutive CTO patients (75.5% 
>6 weeks CTO age) were enrolled after successful guidewire recanalization. The primary 
endpoint was 6-month angiographic binary restenosis (>=50% stenosis) within the treated 
segment assessed by an independent core laboratory. Independently adjudicated clinical 
and angiographic adverse outcomes, including target vessel failure (TVF), target lesion 
revascularization (TLR), stent thrombosis, and stent fracture were evaluated.
Results: Baseline characteristics included: diabetes, 24.5%; prior infarction, 33.5%; 
mean stent length, 56.4 mm; overlapping stents, 91.2%. A total of 196 patients (98.0%) 
received treatment with SES; overall procedural success was 88.5%. At 6-month 
angiography (N=169, 84.5%), binary restenosis rates were: 7.5% in-stent, 13.6% in-
segment, and 22.6% in ‘working length’ representing the entire angioplasty treatment 
segment. Rates of 6-month TLR, myocardial infarction (MI), and TVF were 6.1%, 1.0%, 
and 6.1%, respectively. Stent thrombosis occurred in 1 patient (0.5%) at 115 days. Using 
logistic regression modeling that included propensity score adjustment, the odds ratio for 
binary restenosis with SES compared with a historical bare metal stent control group was 
0.17 (95% CI, 0.09-0.30). No significant differences in adverse events occurred between 
patients identified with stent fracture (N=32, 16%) and those without.
Conclusions: Despite greater lesion complexity than in prior CTO trials, percutaneous 
revascularization with SES results in substantial reductions in angiographic restenosis 
and the need for repeat revascularization. For the time period examined, the use of 
SES in this setting appears safe. These findings further support the use of SES in CTO 
revascularization.
1:54 p.m.
2901-14 High-risk Patient Use of the TAXUS Express2 Paclitaxel-
eluting Stent: Two-Year Insights From the 7300-Patient 
ARRIVE Registry Program
John M. Lasala, David A. Cox, Stephen R. Mascioli, Donald S. Baim, ARRIVE 
Participating Physicians, Washington University School of Medicine, St. Louis, MO
Background: To determine if the long term safety and effectiveness of drug-eluting stents 
(DES) observed in clinical trials reflects results observed in the more complex patients 
(pts) treated in routine practice, follow-up data through 2 years were compiled on 7,307 
pts enrolled in the TAXUS® Express2™ ARRIVE program.
Methods: Consecutively enrolled pts (99 US sites) receiving the TAXUS stent were 
prescribed aspirin and thienopyridine therapy (minimal duration 6 months), with monitoring 
and independent adjudication of all events.
Results: Simple-use (single vessel/stent, 2.5-3.5 mm, length <28 mm) ARRIVE pt outcomes 
confirm the favorable TAXUS stent results seen in clinical trials. The more complex expanded-
use (Ex) pts had slightly higher adverse event rates in year 1 (Table 1), but those rates fell for 
all pts in year 2, with similar rates for simple-use and Ex groups (except for year 2 death).
Conclusion: The real-world ARRIVE program includes the broad spectrum of disease 
routinely treated with DES. Ex pts showed expectedly higher adverse event rates in year 
1 compared to simple-use, but then had similar TAXUS-stent related outcomes in year 2, 
suggesting most of the increased risk of the Ex is limited to year 1. Even for Ex pts, the 
TAXUS outcomes in ARRIVE for year 1 and year 2 compare well to the expected CABG 
mortality in year 1 (4.3%) and year 2 (2.3%) drawn from randomized trial data comparing 
CABG to complex PCI. Complete 2-year data for the full cohort and various high-risk 
subgroups will be presented. 
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Table 1. Outcomes at 1 and 2 Years in ARRIVE
Event
Rate
(%)*
Simple Use** Expanded Use Diabetes (medication)
0-1y
n=2525
1-2y
n=805
0-1y
n=4454
1-2y
n=1475
0-1y
n=1952
1-2y
n=611
All Death 2.3 1.2 4.1 2.6 5.0 3.1
Cardiac 
Death 0.6 0 1.3 0.2 1.6 0.2
MI 1.3 0.6 1.8 0.4 2.5 0.5
QWMI 0.5 0.2 0.7 0.2 0.7 0
TVR 3.3 2.0 6.1 2.5 4.8 2.6
ARC
ST*** 0.9 0.6 2.2 0.7 2.2 1.0
Expanded-use High Risk Subgroups
Event
Rate
(%)
Acute MI Long lesion(≥28 mm) 
Small vessel
(≤2.5 mm) 
0-1y
n=856
1-2y
n=224
0-1y
n=906
1-2y
n=321
0-1y
n=2132
1-2y
n=675
All Death 3.7 3.1 4.2 2.5 3.6 2.1
Cardiac 
Death 0.9 0.9 1.4 0 1.1 0.1
MI 1.6 0.4 4.0 0.3 2.3 0.4
QWMI 0.1 0.4 1.9 0.3 0.8 0.1
TVR 4.2 1.8 8.5 3.1 6.1 2.7
ARC
ST 2.7 0.9 3.8 1.6 2.3 0.7
Event
Rate
(%)
Multivessel
stenting
Bifurcated
lesion
Vein graft
stenting
0-1y
n=1097
1-2y
n=389
0-1y
n=527
1-2y
n=183
0-1y
n=449
1-2y
n=136
All Death 4.2 1.8 5.3 1.6 5.3 4.4
Cardiac 
Death 1.9 0.3 2.3 0 1.1 0.7
MI 3.1 0.5 2.3 0 1.8 0.7
QWMI 1.4 0 0.6 0 0.4 0.7
TVR 7.7 3.3 8.9 3.8 5.6 3.7
ARC
ST 2.9 1.0 3.0 0.5 2.4 0.7
* Events adjudicated by an independent Clinical Events Committee; cardiac death, 
myocardial infarction (MI), Q-wave MI (QWMI), and target vessel revascularization 
(TVR) are TAXUS-stent related. Data for 1-2 years are from ARRIVE 1 only.
**Simple use (36% of pooled ARRIVE patients) excludes patients with baseline AMI, 
left main, graft, chronic total occlusion, in-stent restenosis, failed brachytherapy, 
bifurcation, ostial, severe tortuosity, multivessel stenting, moderate/severe calcification, 
RVD<2.5mm, RVD>3.75mm, lesion length>28mm, cardiogenic shock, renal 
dysfunction.
*** Stent thrombosis (ST) reported as ARC Definite + Probable, Total (Cutlip, et al. 
Circulation 2007;115:2344)
2:00 p.m.
2901-15 Predictors of Stent Thrombosis and Revascularization 
in Real-world Use of the TAXUS Express2 Paclitaxel-
eluting Stent: Insights From the 7300-Patient ARRIVE 
Program
John M. Lasala, David A. Cox, Stephen R. Mascioli, Donald S. Baim, ARRIVE 
Participating Physicians, Washington University School of Medicine, St. Louis, MO
Background: This study examined predictors of stent thrombosis (ST) and TAXUS-
related target vessel revascularization (TR-TVR) in the ARRIVE registry.
Methods: Consecutively-enrolled patients (pt) (N=7307; 99 US sites) receiving ≥1 TAXUS 
stent were followed with all adverse events adjudicated by an independent committee 
including ST by ARC and TR-TVR per protocol. Dual antiplatelet therapy ≥6 months 
(M) was prescribed. Baseline characteristics (>30) were assessed using step-wise Cox 
proportional hazards regression.
Results: Outcomes data are available for 6979 pts at 1 yr and 2319 at 2 yrs. Of 123 ST in 
yr 1 (1.7 %), 74 (1.0%) occurred ≤30 days; VLST (>1 yr) was 0.8%. At 1 yr TR-TVR was 
5.1% (355); non-TR TVR was 1.6% (111). TVR in yr 2 was lower (2.3% TR; 0.3% non-TR). 
Predictors (Table 1) for ST <1 yr and VLST included thienopyridines (TP) <6M but were 
otherwise distinct with predictors for ST <1 yr relating mostly to lesion characteristics and 
VLST predictors to biologic pt factors. TR-TVR <1 yr had 8 independent predictors mostly 
related to lesion factors with only CTO stenting and previous PCI in yr 2.
Conclusions: While overall ST rates were as expected for a complex real-world 
experience, lesion factors and early TP discontinuation increased the rate by 1.6-4 
fold. Different ST predictors >1 yr suggest pathophysiology differences. Complex lesion 
characteristics increase TR-TVR by 1.3-1.8 fold. Similar analyses will be available in 
March 2008 for ST and TVR risk factors in the full ARRIVE cohort to 2 yr follow-up. 
Table 1. Predictors for Stent Thrombosis and TVR in the TAXUS ARRIVE Registry
Predictor - ARC 
Stent Thrombosis 
(ST), Definite + 
Probable, Total*
Hazard Ratio [95% Confidence Interval]
0-1 yr (n=123 ST)
Pooled ARRIVE (N=7307)
>1-2 yrs (n=16 ST)
ARRIVE 1 (N=2487)
Thienopyridine <6 
months 4.07 [2.84, 5.82] 5.99 [2.15, 16.67]
Smoking at baseline 2.61 [1.82, 3.74] NS
Congestive heart 
failure 2.21 [1.32, 3.71] NS
Lesion length >28 
mm
1.93 [1.24, 3.00] NS
Multiple stents 1.69 [1.15, 2.50] NS
Lesion calcification 
(moderate/severe) 1.63 [1.11, 2.41] NS
Minimum reference 
vessel diameter** 0.38 [0.24, 0.60] NS
Failed brachytherapy NS 17.77 [2.26, 139.50]
CTO stenting NS 5.10 [1.14, 22.84]
Prior myocardial 
infarction NS 3.56 [1.23, 10.36]
Age** NS 0.95 [0.91, 0.99]
Predictor - TAXUS® 
stent-related 
Target Vessel 
Revascularization 
(TVR) 
Hazard Ratio [95% Confidence Interval]
0-1 yr (n=355 TVR)
Pooled ARRIVE (N=7307)
>1-2 yrs (n=53 TVR)
ARRIVE 1 (N=2487)
Bifurcated lesions 1.46 [1.07, 2.00] NS
ISR stenting 1.78 [1.28, 2.48] NS
Lesion length >28 
mm
1.66 [1.24, 2.20] NS
LAD as target vessel 1.40 [1.13, 1.74] NS
Previous CABG 1.46 [1.12, 1.90] NS
Lesion calcification 
(moderate/severe) 1.43 [1.11, 1.82] NS
Multiple stents 1.38 [1.09, 1.74] NS
Thienopyridine <6 
months 1.32 [1.00, 1.73] NS
Gender (male) 0.67 [0.54, 0.83] NS
Minimum reference 
vessel diameter** 0.63 [0.48, 0.82] NS
Age** 0.97 [0.96, 0.98] NS
CTO stenting NS 4.08 [1.47, 11.32]
Previous PCI NS 1.96 [1.13, 3.37]
* Academic Research Consortium, Cutlip et al. Circulation 2007;115:2344
**
 Continuous variable
Variables listed reached statistical significance (p<0.05); CABG=coronary artery 
bypass graft; CTO=chronic total occlusion; ISR=in-stent restenosis; LAD=left anterior 
descending artery; PCI=percutaneous coronary intervention
2:06 p.m.
2901-16 A Meta-analysis Evaluating Long-term Safety and 
Efficacy of Drug-eluting Stents Compared to Bare-
metal Stents for Off-label Indications
Nirat Beohar, Ata Erdogan, Matthew Harinstein, Sheridan N. Meyers, Jiezhun Gu, Karen 
Pieper, Charles J. Davidson, Northwestern University Feinberg School of Medicine, 
Chicago, IL
Background: Controversy exists whether drug eluting stents (DES) improve efficacy but 
compromise safety compared to bare metal stents (BMS) when used in Off-label indications.
Methods: Using a meta-analytical approach, we evaluated the safety and efficacy of 
DES compared to BMS from all published registries (US and outside US, 2000-2007, 
n=1252 patients) with follow up between 6 and 24 months. Each series enrolled patients 
undergoing PCI with DES or BMS for only one lesion type [Left main lesions (n = 386), 
Saphenous Vein grafts (SVG) lesions (n = 226), Ostial lesions (n = 438) and Total 
Occlusions (n = 202)]. Six month events are presented when the estimates of 1-2 year 
rates were too unstable.
Results: Long -Term Outcomes of DES versus BMS in Off-Label Use [OR (95% CI)] 
Myocardial 
Infarction
Target Vessel 
Revascularization Death
Left Main 1-2 years0.31(0.11-0.88)
1-2 years
0.23 (0.10-0.52)
1-2 years
0.60 (0.28-1.3)
SVG 6 months0.90(0.28-2.9)
6 months
0.17(0.05-0.59)
6 months
0.72 (0.06-8.2)
Ostial 1-2 years0.46 (0.04-5.2)
6 month
0.36 (0.12-1.10)
1-2 years
0.69 (0.15-
3.15)
Total 
Occlusion
6 months
0.28 (0-0)
6 months
0.27 (0.08-0.90)
1-2 years
0.50 (0-0)
Overall Group 1-2 years0.31 (0.10-0.88)
6 months
0.24 (0.12-0.45)
1-2 years
0.60 (0.27-
1.29)
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Conclusions: In this meta-analysis comparing DES to BMS for Off-label PCI:
1. There is a significant 64-83% decrease in the need for target vessel revascularization 
with DES compared to BMS across lesion subtypes.
2. There was a statistically significant decrease in risk of myocardial infarction with DES 
for left main PCI and in the overall group, and no increase in this risk for SVGs, ostial 
lesions or total occlusions.
3. There was no mortality hazard with the Off-label use of DES compared to BMS for any 
lesion subtype evaluated or for the overall group.
2:12 p.m.
2901-17 Comparison of the Systemic Levels of Inflammatory 
Markers After Percutaneous Coronary Intervention With 
Bare-Metal Versus Sirolimus Eluting Stents
Abdallah G. Rebeiz, Elie Zoghbi, Rami Harb, Sonia Youhanna, Adel Dimassi, Antoine 
Nasrallah, Jaber Sawaya, Walid Gharzeddine, Samir Alam, American University of 
Beirut Medical Center, Beirut, Lebanon
Background: Percutaneous coronary intervention (PCI) with bare metal stent (BMS) 
deployment has been shown to induce a rise in systemic levels of inflammatory markers 
such as C-reactive protein (CRP), interleukin (IL)-6, and monocyte chemoattractant 
protein (MCP)-1. Our aim is to study whether the use of sirolimus-eluting stents (SES) 
modulates the rise in systemic levels of CRP, IL-6, and MCP-1.
Methods: Patients with stable angina undergoing native vessel PCI on a single coronary 
de novo stenosis were enrolled in an open label non randomized fashion into one of 
two groups: the BMS group (cobalt-chromium stent) or the SES group (Cypher stent). 
Blood samples for assays were obtained by phlebotomy pre-PCI, 24 hours post PCI, and 
30 days post-PCI. Plasma concentrations of CRP were measured using immunological 
agglutination. Plasma IL-6 and MCP-1 levels were measured using enzyme linked 
immunosorbent assay (ELISA), by a technician blinded to the choice of stent.
Results: A total of 41 patients were enrolled (21 in the BMS group and 20 in the SES 
group). The baseline plasma concentrations of all markers were comparable between 
groups. At 24 hours, the mean plasma CRP concentration in the SES group was 20.21 
mg/dl vs. 8.95 mg/dl in the BMS group (p=0.15). At 30 days, mean CRP concentrations 
decreased to 4.64 mg/dl in the SES group vs. 3.35 mg/dl in the BMS group (p=NS). 
The mean plasma IL-6 concentration at 24 hours was 25.41 pg/ml in the SES group vs. 
17.44 pg/ml in the BMS group (p=0.17). At 30 days, mean IL-6 levels decreased to 10.33 
pg/ml in the SES group vs. 11.51 pg/ml in the BMS group (p=0.48). The mean plasma 
MCP-1 concentration at 24 hours was 382.38 pg/ml in the SES group vs. 329.04 pg/ml 
in the BMS group (p=0.2). At 30 days, plasma MCP-1 concentrations were similar in both 
groups (6.06 pg/ml in the BMS group vs. 6.04 pg/ml in the SES group, p=NS).
Conclusions: The use of SES did not inhibit the rise in systemic concentrations of CRP, IL-6, and 
MCP-1 at 24 hours or 30 days post PCI, compared with BMS. At 24 hours post PCI, there was 
a trend for higher systemic levels of all three pro-inflammatory markers among SES recipients 
compared with BMS recipients. A larger study is needed to test the significance of this finding.
2:18 p.m.
2901-18 Gender Difference of Sirolimus-Eluting Stent Expansion 
Evaluated by Intravascular Ultrasound
Shinichiro Yamada, Amane Kozuki, Takatoshi Hayashi, Sachiyo Iwata, Masahiro 
Kumada, Yusuke Kurogane, Yasuyo Taniguchi, Kazuo Mizutani, Katsunori Okajima, Akira 
Shimane, Kensuke Matsumoto, Yasue Tsukishiro, Teishi Kajiya, Himeji Cardiovascular 
Center, Himeji, Japan
Background:Stent thrombosis may occur late after drug-eluting stent implantation, and 
its cause remains unknown. Recent studies revealed that male gender is a risk factor of 
late stent thrombosis (LST). We sought to evaluate the gender difference of intravascular 
ultrasound (IVUS) findings at the time of stent implantation procedure.
Methods:We investigated 133 consecutive lesions treated with sirolimus-eluting stent 
(SES) in stable angina under IVUS guidance. Lesions requiring more than two stents or 
presenting acute coronary syndrome were excluded. One-hundred eleven stents were 
implanted in male patients and 22 stents in females. IVUS analyses were performed 
after primary SES dilatation. Cross sectional area (CSA) of reference segments and stent 
were evaluated.
Results:Reference lumen CSA did not differ significantly between male group and female 
group. Stent size, length and inflation pressure also did not differ. However, female gender 
had a trend toward greater minimal stent CSA (MSCSA) / reference lumen CSA (RCSA) 
ratio. MSCSA against the values predicted by compliance charts was significantly greater 
in female group than in male group. Optimal stent expansion (MSCSA >90% of RCSA and 
all strut apposed) was achieved in 36.3% in female group after primary SES dilatation, 
whereas only 14.4% in male group (p=0.01).
Conclusions:There is a gender difference of SES expansion. High prevalence of stent 
underexpansion may be one of the mechanisms of frequent late stent thrombosis in 
male patients.
Male gender
(n=111)
Female gender
(n=22) P value
Stent size (mm) 3.18 3.07 0.2
Stent length (mm) 21.6 19.8 0.2
Inflation pressure (atm) 16.8 16.6 0.8
Proximal RCSA (mm2) 9.2+-3.5 8.2+-2.3 0.2
Distal RCSA (mm2) 7.5+-2.6 6.6+-2.0 0.2
MSCSA (mm2) 6.3+-3.8 6.1+-2.5 0.7
MSCSA/RCSA 0.762 0.823 0.08
MSCSA/CSA predicted by compliance charts 0.673 0.721 0.04
Optimal SES expansion (%) 14.4 36.3 0.01
2:24 p.m.
2901-19 The Fate of Side-Branches Among Patients treated with 
Zotarolimus-eluting and Paclitaxel-eluting stents: An 
ENDEAVOR-IV Substudy
Ajay Kirtane, Laura Mauri, Jeffrey Popma, Martin B. Leon, Kweli Thompson, Columbia 
University Medical Center, New York, NY, Harvard Clinical Research Institute, Boston, MA
Background: The ENDEAVOR IV randomized trial demonstrated similar rates of target 
vessel failure with the Endeavor stent (ZES) and Taxus stent (PES) at one year. However, 
a greater rate of periprocedural MI was observed with PES vs ZES.
Objectives and Methods: A possible explanation of this difference might be related to 
stent-specific differences in the fate of sidebranches (SB) within the target vessel 
treatment site. Patients with target lesions with one or more SB >1 mm in diameter (79% 
of all patients; 597 with ZES and 619 with PES) were eligible for a detailed SB analysis 
by the angiographic core lab.
Results: Baseline and post-procedural characteristics including treated vessel, ACC/AHA 
lesion class, post-stent MLD, percent diameter stenosis, and acute gain were similar 
in both groups. While there were no differences in final TIMI flow or abrupt closure/
dissection within the main target vessel, there were trends toward a greater frequency 
of SB closure and reduced SB flow with PES compared to ZES (Table). These findings 
were first manifest after the initial stent implantation (SB occlusion: 4.0% PES vs 2.2% 
ZES, p=0.032; reduced SB flow: 6.5% vs 3.6%, p=0.006), with similar trends observed 
on the final angiogram (SB occlusion: 3.4% vs 2.0%, p=0.069; reduced SB flow: 5.5% vs 
3.6%, p=0.062).
Conclusions: In this post-hoc exploratory analysis of patients with SB> 1 mm in 
ENDEAVOR IV, treatment with PES was associated with a greater incidence of SB 
occlusion and decrements in SB flow compared to ZES. 
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2803-3 Completeness of Revascularisation and Event Free 
Survival in the ARTS II Trial
Patrick W. Serruys, Benno J. Rensing, Marcel van den Brand, Kristel Wittebols, Marie-
Claude Morice, ARTS II Investigators, Thorax Center, Rotterdam, The Netherlands
Background: Incomplete revascularization (IR) is a known predictor of outcome after 
multivessel (MV) PCI and CABG. Drug eluting stents (DES) might improve outcome after 
MV stenting. We conducted a subanalysis of the ARTS2 trial in which MV disease patients 
were treated with DES. The ARTS1 (randomized MV non-DES PCI vs CABG) surgical 
arm was used as control.
Methods: Enrollment of ARTS2 patients was stratified to ensure comparibility with the 
ARTS1 population. Completenes of revascularisation was assessed by an independent 
corelab. The primary end-point was 1 year MACCE free survival (Death, MI, CVA, 
revascularization). All events were centrally assessed.
Results: Of 607 enrolled patients 588 angiograms were available for review. 360 pts had 
complete revascularization (CR), 228 were incompletely revascularized (IR).
1 year outcome
Arts2 Arts1 PCI Arts1 CABG
CR n=360 IR n=228 CR n=406 IR n=170 CR n=477 IR n=90
Death 0,6% 1,8% 1,7% 3,5% 2,5% 4,4%
MI 0,8% 1,3% 4,9% 5,9% 3,4% 4,4%
Revasc 6,1% 8,3% 15,1% 20% 2,3% 3,3%
Death/Mi/stroke 1,7% 4,8%* 8,9% 10,6% 7,8% 8,9%
MACCE free 92% 87%* 77% 69% 90% 88%
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Conclusion: CR patients in ARTS2 had a better 1 year outcome than IR patients. In 
comparison to the ARTS1 MV PCI patients, outcome improved in both the CR and IR 
groups and is comparable to the ARTS1 surgical group. 3 year outcomes will be presented 
at the meeting.
1:15 p.m.
2803-4 Three-Year Outcomes of Sirolimus-Eluting Stents for 
the Treatment of In-Stent Restenosis: The SISR Trial
David Holmes, Jeffrey Popma, Peter Fitzgerald, Paul Tierstein, Lowell Satler, Michael 
Sketch, Sidney Cohen, Mayo Clinic, Milwaukee, WI
Purpose: To compare the use of vascular brachytherapy to the sirolimus-eluting 
CYPHER® Stent for the treatment of restenosis occurring within a previously placed bare-
metal stent.
Methods: A multicenter, prospective, randomized trial enrolling patients at 26 US sites. 
Patients had ISR lesions in native coronary arteries >15mm to < 40mm in length and > 
2.5mm to < 3.5mm in diameter. Bayesian methods were used to include additional Brachy 
control data from the Gamma I & II studies. Primary endpoint of target vessel failure 
(TVF), defined as cardiac death, MI or TVR at 9 months was evaluated for non-inferiority 
and superiority of CYPHER® vs. Brachy.
Results: 384 patients were randomized 2:1 (259 CYPHER®: 125 Brachy). There were 
no significant differences in demographic or procedural characteristics. TVF at 9 months 
was 21.6% with Brachy and 12.4% with CYPHER® (RR 1.7; [95% CI 1.1-2.8], p=0.02). 
At 2-years, MACE was 17.0% for CYPHER® and 24.8% for Brachy. The rate of stent 
thrombosis during 2-year follow-up by the prespecifed protocol definition was 1.2% for 
CYPHER® vs. 0.0% with Brachy. This difference was not statistically significant. Final 3-
year results will be available at time of presentation.
Conclusions: The sirolimus-eluting CYPHER® stent demonstrated non-inferiority and 
superiority to vascular Brachy at 9 months in the treatment of patients with bare-metal 
stent ISR. Safety measures at 2 years favor the use of the CYPHER® stent. 3-year follow-
up will be presented. 
In- and Out-of-Hospital to 720 Days
Description of Event
CYPHER®
(N=259 
Patients,
N=259 
Lesions)
Brachytherapy
Control
(N=125 Patients,
N=125 Lesions)
P-
Value
MACE (Death, Q wave or non-Q wave MI, 
Em CABG, TLR)
17.0% 
(44/259) 24.8% (31/125) 0.075
Death 1.5% (4/259) 0.8% (1/125) 1.000
Myocardial Infarction (Q Wave or WHO 
Non-Q Wave) 4.6% (12/259) 1.6% (2/125) 0.160
Emergent CABG 0.0% (0/259) 0.0% (0/125) --
Target Lesion Revascularization 13.5% (35/259) 24.0% (30/125) 0.013
Stent Thrombosis 0.0% (0/259) 0.0% (0/125) --
Acute Thrombosis 0.0% (0/259) 0.0% (0/125) --
Subacute Thrombosis 0.0% (0/259) 0.0% (0/125) --
Late Thrombosis 1.2% (3/259) 0.0% (0/125) 0.554
1:30 p.m.
2803-5 Impact of Intravascular Ultrasound Guidance on 
Long-Term Clinical Outcomes in Patients Undergoing 
Percutaneous Coronary Intervention for Unprotected 
Left Main Disease
Myeong-Ki Hong, Duk-Woo Park, Young-Hak Kim, Won-Jang Kim, Jon Suh, In Hyun 
Jung, Jeong Hoon Kim, Seung-Whan Lee, Cheol Whan Lee, Jae-Joong Kim, Seong-
Wook Park, Seung-Jung Park., MAIN-COMPARE Investigators, Asan Medical Center, 
Seoul, South Korea
Background: Data regarding influence of intravascular ultrasound (IVUS) guidance on 
long-term outcomes in patients receiving coronary stenting for unprotected left main 
coronary artery (ULMCA) disease are limited. .
Methods: Between Jan, 2000 and June, 2006, a total of 1138 patients with ULMCA 
stenosis underwent percutaenous coronary intervention (PCI) at 12 academic institutions 
in Korea. Bare-metal stents and drug-eluting stents were implanted in 336 and 805 
patients, respectively.
Results: A total of 843 (75.3%) patients received IVUS-guided PCI. Patients with IVUS-
guided PCI were significantly younger and had less prevalence of hypertension, chronic 
renal failure, myocardial infarction, left ventricular dysfunction (EF<40%), and high 
Euroscore (≥ 6). Median duration of follow-up was 33.3 months (IQR 22.6-47.9). After 
adjustment of baseline risks, PCI with IVUS guidance was significantly associated with 
lower incidence of death or the composite of death, Q-wave myocardial infarction or target 
vessel revascularization than those without IVUS guidance (Table).
Conclusions: In patients with ULMCA stenting, IVUS guided-PCI was significantly 
associated with decrease of long-term mortality compared with angiography-guided PCI. 
IVUS (+) IVUS (-) Adjusted HR (95% CI) P
Clinical events Unadjusted 3-year
cumulative incidence
Death 4.4% 13.3% 0.36 (0.19-0.68) 0.002
Q-MI 0.4% 2.2% 0.60 (0.001-443.97) 0.88
TVR 11.2% 11.2% 0.77 (0.47-1.27) 0.31
Death/Q-MI/TVR 14.5% 24.5% 0.60 (0.42-0.87) 0.007
Q-MI:Q-wave myocardial infarction, TVR: target vessel revascularization
1:45 p.m.
2803-6 Predictors of Angiographic Stent Fracture and Stent 
Fracture with Restenosis after Sirolimus-eluting stent 
(SES) Implantation
Kazushige Kadota, Kazuaki Mitsudo, Tsuyoshi Goto, Hiroyuki Yamamoto, Harumi Kato, 
Yasushi Fuku, Shingo Hosoki, Hiroyuki Tanaka, Kanjyo Yamamoto, Seiji Habara, Daiji 
Hasegawa, Masao Imai, Kurashiki Central Hospital, Kurashiki, Japan
Background:Stent fracture is related to in-stent restenosis after Sirolimus-eluting stent 
(SES) implantation. However there was no data of systematic evaluation of predictors 
of stent fracture and stent fracture with restenosis. We evaluated the angiographic stent 
fracture and restenosis and clarify their predictors.
Methods and Results: From Nov. 2002 to June 2006, consecutive 1808 patients with 
2920 lesions were treated with PCI using SES. Of these, 1491 patients with 2357 lesions 
were angiographically followed after 6-8 months. The angiographic follow-up rate was 
80.7%. Angiographic stent fracture was defined as obvious separation of stent segments. 
Lesion complexity, QCA data, stenting variables were examined as predictor of stent 
fracture and stent fracture with restenosis. Furthermore, the effect of pre-PCI specific 
coronary motion (5 types: lever, bend, multiple bend, crease, squeezing) on the restenosis 
of stent fracture were studied. Total angiographic restenosis rate was 11.2% (261 lesions). 
Prevalence of stent fracture and stent frcature witn restenosis was 3.9% (92 lesions) 
and 1.1% (27 lesions) respectively at follow up CAG. Multivariate analysis revealed that 
positive predictors of stent fracture and stent fracture with restenosis were aorto-ostial 
lesion, severe angulated lesion, saphenous vein graft lesions and overlapping stenting. 
In-stent restenosis lesion was a negative predictor of stent fracture.The incidence of 
lesions with pre-PCI coronary artery motion was higher in stent-fracture lesions with 
restenosis than those without restenosis, 73.9% and 17.6% (P<0.001).
Conclusions:
Both stent fracture and stent fracture with restenosis is related to the anatomical 
and procedural factors. However, stent fracture was not always related to restenosis. 
Specific coronary motion could be related to stent fracture with restenosis. 
2:00 p.m.
2803-7 Independent Predictors of Stent Thrombosis After 
Implantation of Drug-Eluting Stents in Complex 
Coronary Lesions: Insights From the Prospective, 
Nonrandomized Drug-Eluting Stent in Real World 
(DESIRE) Trial
Ricardo A. Costa, Amanda Sousa, J. Ribamar Costa, Jr., Adriana Moreira, Galo 
Maldonado, Manuel Cano, Luiz F. Tanajura, Ibraim M. Pinto, Alexandre Abizaid, Rodolfo 
Staico, Luiz A. Mattos, Fausto Feres, Adib D. Jatene, J. Eduardo Sousa, Hospital do 
Coração - Associação do Sanatório Sírio, São Paulo, Brazil
Background: In the DESIRE trial, unselected pts coming for routine or emergency 
percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation were 
consecutively enrolled at one center. Methods: From May/02 to May/07, 2,081 pts (2,864 
lesions) were treated with 3,120 DES. Stent thrombosis (ST) was defined according to the 
definitions proposed by the Academic Research Consortium. Results: Mean age was 64 
years, 29% had diabetes, 21% had prior MI, and 51% had prior revascularization; 41% 
presented with acute coronary syndrome (15% ST-elevation MI); 59% had multivessel 
disease, and baseline lesion morphology showed high complexity in 66% (type B2/C), 
including 26% of lesions with mod./severe calcium, 5% in-stent restenosis, 6% SVG, 5% 
ostial location, and 3% thrombus. At clinical follow-up (97%, mean time: 2.6±1.2 years), 
overall ST rate was 1.6% (n=33), Table. Independent predictors of ST were: PCI in the 
setting of acute MI [hazard ratio (HR) 11.2; 95%CI 1.6-7.4, p=0.001], lesion length (HR 
4.6; 95%CI 1.2-2.3, p=0.031), mod./severe calcium (HR 13.1; 95%CI 1.5-6.7, p<0.001), 
and residual stenosis within the stented segment (HR 14.5; 95%CI 1.0-1.1, p<0.001). 
Conclusions: In the DESIRE trial, overall ST rate up to 5 years clinical follow-up after 
implantation of DES was 1.6%, and occurred mostly between 1 and 12 months (late 
ST). Independent predictors of ST were primary PCI, long lesions, significant lesion 
calcification, and postprocedural in-stent residual stenosis. 
Stent thrombosis Definite Probable Possible Total
Acute (0-24 hours) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Sub-acute (1-30 days) 7 (0.3%) 1 (0.05%) 0 (0%) 8 (0.35%)
Late (1-12 months) 5 (0.25%) 0 (0%) 11 (0.55%) 16 (0.8%)
Very late (>12 months) 5 (0.25%) 0 (0%) 4 (0.2%) 9 (0.45%)
Total 17 (0.8%) 1 (0.05%) 15 (0.75%) -
2:15 p.m.
2803-8 One year Clinical and Angiographic Results 
in Diabetics from Endeavor IV: A Randomized 
Comparison of the Endeavor Drug (ABT-578) Eluting 
Stent System versus Taxus in De Novo Native Coronary 
Lesions
Martin B. Leon, Laura Mauri, Charles O’Shaunessy, Paul Overlie, Ajay Kirtane, Jeffrey 
Popma, Peter Fitzgerald, Columbia University Medical Center, New York, NY
Background_ PCI in diabetic patients is associated with increased rates of restenosis 
and worse long-term outcomes compared to nondiabetic patients.
Methods_ The 12 month results of the ENDEAVOR IV trial evaluating the safety and 
efficacy of the Endeavor Zotarolimus-eluting stent (ZES) vs the Taxus Paclitaxel-eluting 
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stent (PES) in 1548 patients undergoing elective PCI of de novo native lesions ≤27 mm 
with vessel diameters 2.5-3.5 mm were recently presented. We sought to assess the 
outcomes of ZES vs PES in the 477 diabetic patients (31%) enrolled in this trial.
Results_Baseline characteristics were similar among ZES (n=241) and PES (n=236) 
patients in the diabetic subgroup, with slightly longer lesion lengths in the PES group. 
Overall clinical outcomes were not statistically different between ZES and PES treated 
patients in the diabetic subgroup (Table).
Complete one-year data describing baseline characteristics, procedural and angiographic 
data for the diabetic subset of the ENDEAVOR IV trial will be presented in detail.
Conclusions_ Clinical outcomes were similar among diabetic patients treated with 
ZES and PES. These findings parallel the overall ENDEAVOR IV trial results, which 
demonstrated similar safety and efficacy of the Endeavor ZES and the Taxus PES. 
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2902-5 Multicenter Experience with Transapical Aortic Valve 
Implantation: Early Results and Hemodynamic 
Performance
Todd Dewey, Thomas Walther, Ernst Wolner, Matt Williams, Lars Svensson, Jill Fowler, 
Morley Herbert, Craig Smith, Gerhard Wimmer-Greinecker, Friedrich Mohr, Michael 
Mack, Medical City Dallas Hospital, Dallas, TX, Cardiopulmonary Research Science and 
Technology Institute, Dallas, TX
Background: Feasibility of Transapical Aortic Valve Implantation (TAVI) has previously 
been demonstrated in non-surgical candidates with critical aortic stenosis (AS). We report 
early outcomes of a large population having TAVI from multiple centers in the United 
States and Europe.
Methods: Between December 2004 and October 2007, 145 patients underwent 
transapical aortic valve implantation in Europe and the United States of a balloon 
expandable pericardial valve. Average patient age was 82.9 years, 73% (106/145) were 
female, and the average logistic EuroScore was 31.9 %. Procedural outcomes were 
tracked and surveillance echocardiography was used to follow post implant peak and 
mean gradients, as well as effective orifice area (EOA).
Results: 30 day mortality was 11.7% (17/145), with an additional 23 deaths (15.8%) 
occurring after 30 days. Baseline mean and peak gradients improved from 42.9 ± 12.8 
mmHg and 70.8 ± 20.5 mmHg respectively to 7.6 ± 3.5 mmHg and 14.5 ± 6.3 mmHg. 
EOA increased on average from 0.58 ± 1.8 cm2 to 1.51 ± 0.42 cm2. 72.5 % of patients had 
1+ or less perivalvular leak on 30 day echocardiogram.
Conclusions: Transapical insertion of a balloon expandable bioprosthesis is associated 
with marked improvement in EOA, mean and peak transvalvular gradients and acceptable 
mortality in a high risk population with aortic stenosis.
1:06 p.m.
2902-6 A Percutaneous Ventricular Partitioning Device for 
Treatment of Anterior Wall Abnormalities and LV 
Aneurysms
Nicolas Majunke, Sinisa Gradinac, Albrecht Elsässer, Nina Wunderlich, Horst Sievert, 
CardioVascular Center, Frankfurt, Germany
Background: Surgical and medical treatment of chronic left heart failure after myocardial 
infarction has major limitations. A new percutaneous approach allows for the isolation of 
the apical dysfunction region. The hypothesis is that the decreased ventricular volumes 
and improved hemodynamics will prevent remodelling of the surrounding normal 
myocardium and preserve overall left ventricular function.
Methods: The Ventricular Partitioning Device (VPD) implant consists of an expended 
Nitinol frame in the configuration of an inverted umbrella covered with an ePTFE membrane. 
It is designed to be implanted into the left ventricular apex. Implantation was attempted in 
18 patients with a mean age of 59.4 years (43-71), reduced left ventricular function (EF 
≤40), apical wall hypo-/akinesia and at least NYHA class II. NYHA classification, TTE and 
6 min walk test were repeated after 6 and 12 months.
Results: Successful device implantation was achieved in 15 of 18 patients. In three 
patients implantation was not possible due to anatomical reasons. One device was 
misplaced and had to be removed surgically. Two patients suffered from minor groin 
complications. During follow-up, one patient died due to non cardiac reasons, one minor 
stroke after 14 months and one TIA after 9 months occurred.
Conclusions: The VPD is the first catheter-based system to treat LV wall motion 
abnormalities and aneurysms. Implantation of the device is feasible and safe. The 6 and 
12 month data show improved functional and hemodynamic outcome.
Baseline 6 months 12 months
NYHA class 2.2 ± 0.6 1.3 ± 0.5 1.3 ± 0.5
6 min. walk (m) 370 ± 117 390 ± 114 410 ± 141
LV EF (%) 27 ± 7.5 32 ± 7.3 31 ± 8.3
LVEDV (ml) 260 ± 48 215 ± 33 235 ± 62
LVESV (ml) 191 ± 46 145 ± 29 162 ± 48
1:12 p.m.
2902-7 Randomized, Multi-Center Evaluation of the 
Pimecrolimus-Eluting and the dual Pimecrolimus/
Paclitaxel-Eluting Coronary Stent System in Patients 
with De Novo Lesions of the Native Coronary Arteries: 
GENESIS Trial 6 month Results
Keith D. Dawkins, Stefan Verheye, Joseph Dens, Wolfgang Rutsch, Didier Carrié, 
Chaim Lotan, Christoph Dubois, Alexandra Lansky, Louise Gambone, Vicki 
Hacker, Southampton University Hospital, Southampton, United Kingdom, Antwerp 
Cardiovascular Center Middelheim, Antwerp, Belgium
Background: The GENESIS study is designed to evaluate the safety, performance and 
efficacy of the Conor cobalt chromium reservoir based coronary stent system eluting 
either pimecrolimus (CORIO) or a dual drug delivery of pimecrolimus and paclitaxel 
(SYMBIO) compared to the CoStar paclitaxel eluting stent (control) for the treatment of 
single de novo coronary lesions. The Conor stent provides a novel drug delivery system 
utilizing discrete reservoirs as a repository where a matrix of bio-resorbable polymer and 
drug are deposited. This allows different drugs in adjacent reservoirs to be delivered with 
precise control of the release kinetics for each formulation
Methods: GENESIS is a single blinded study enrolling 248 patients from 18 sites in 
Europe and Israel, Patients were randomized 2:2:1 to CORIO, SYMBIO, or the CoStar 
control arm, respectively. Primary endpoint was 6-month angiographic in-stent late lumen 
loss. 30 patients per treatment arm were scheduled to undergo IVUS at baseline and 6 
month follow-up.
Results: Baseline demographics for the 3 groups were similar. However, there were 
more diabetic patients in the Costar control arm (36%) compared to the CORIO (32%) 
and SYMBIO (18%) arms (p=0.018), yet the highest percentage of insulin dependent 
diabetics were in the CORIO arm (47%) compared to Costar (6%) or SYMBIO (12%) 
(p=0.016). Procedure success was high in all 3 groups at 94%, 100%, and 100% for 
CORIO, SYMBIO, and CoStar, respectively.
Blinded, aggregate, 30 day MACE rates are 2.4%, (Q-wave MI 0.8%, non Q-wave MI 
(1.6%), target vessel revascularization 0.4%, death 0 %). Overall stent thrombosis 
rate was 0.8%. Pt. follow up for primary endpoint will be completed in December 2007. 
Conclusions: The GENESIS trial is the first ever to utilize dual drug delivery from adjacent 
reservoirs for treatment of de novo coronary lesions. The presentation will include the final 
6-month angiographic, IVUS and clinical data. 
1:18 p.m.
2902-8 Preliminary Results of the Hydroxyapatite Non-polymer-
based Sirolimus-eluting Stent for the Treatment of 
Single De Novo Coronary Lesions: A First-in-Human 
Analysis of a Third-generation Drug-eluting Stent (DES) 
System
Alexandre Abizaid, Jose de Ribamar Costa, Jr., Ricardo Costa, Luis Fernando Tanajura, 
Fausto Feres, Rosilei Graebin, Rodolfo Staico, Dimytri Siqueira, Luiz Alberto Mattos, 
Galo Maldonado, Amanda Sousa, J Eduardo Sousa, Instituto Dante Pazzanese de 
Cardiologia, Sao Paulo, Brazil
Background: Recent concerns regarding DES long-term safety have been raised. 
Synthetic polymers have been associated with intensive inflammatory response. Animal 
histopathology and ex-vivo model analysis have shown exacerbated positive vessel 
remodeling possibly caused by local response to the polymer presence. Importantly, the 
association between exacerbated vessel enlargement and very late DES thrombosis 
has been recently demonstrated. Newly developed, the Vestasync™ Eluting Stent (VES) 
combines a stainless steel platform with a nanothin-microporous hydroxyapatite surface 
coating impregnated with a polymer-free Sirolimus formulation (55μm) that elutes drug 
for more than 40 days. Hydroxyapatite has excellent biocompatibility and occurs naturally 
in the body. We sought to investigate the safety, performance and efficacy of this third 
generation polymer-free DES.
Methods: In May 2007, 15 patients with single de novo lesion ≤14mm in length, in native 
coronary arteries of 3.0-3.5mm diameter were consecutively enrolled. Primary endpoints 
were 30 days MACE (safety), and in-stent late lumen loss at 4 months (efficacy). Serial 
angiography and intravascular ultrasound (IVUS) were obtained at index procedure and 
planned to be repeated at 4- and 9-month follow-up. Quantitative angiography and IVUS 
analysis were performed at independent core laboratories.
Results: Baseline characteristics included mean age of 63 years, 33% women, and 16% 
diabetics. LAD was the prevalent target vessel (56%). Reference diameter and lesion 
length were 2.7± 0.3mm and 10 ± 2.0mm, respectively. VES was successfully implanted 
in 100% of lesions with final TIMI 3 flow obtained in all cases. Post dilatation was required 
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in 56% of the cases. There were no procedure and in-hospital complications. Lifelong 
aspirin and 6-month clopidogrel were prescribed to all patients. At 4-month follow-up, late 
loss was 0.27± 0.2 and % of in-stent neointimal obstruction was 2.8% with no documented 
MACE/binary restenosis.
Conclusions: The 3rd generation DES VES demonstrated safety and excellent acute 
results in the treatment of de novo coronary lesions. Complete 9-month clinical, QCA and 
IVUS data will be presented at the meeting.
1:24 p.m.
2902-9 Angiographic and Ultrasonographic Results of the SISC 
(Stent in Small Coronaries) Registry
Daniel Chamié, J Ribamar Costa, Jr., Alexandre Abizaid, Fernando Devito, Fausto 
Feres, Marcelo Gottschald, Luiz Alberto P. Mattos, Rodolfo Staico, Andrea Abizaid, 
Ricardo Costa, Amanda G.M.R. Sousa, J Eduardo Sousa, Instituto Dante Pazzanese de 
Cardiologia, Sao Paulo, Brazil
Background: PCI in small vessels (SV) represent a frequent and challenging scenario 
in interventional cardiology with restenosis rates >30% after bare-metal stents. Part of 
the problem is the shortage of dedicated stents to this anatomy. The novel CardioMind 
(CMI) Coronary Stent Delivery System (CardioMind Inc.) consists of a bare-metal, 
self-expandable, nitinol stent with ultra-thin struts (0.0024”) incorporated into a 0.014’’ 
guidewire platform. We aimed to compare this device to a conventional thin-strut (0.0039”), 
bare-metal, balloon-expandable stent (Multi-Link Pixel, Guidant Corp) designed for the 
treatment of SV.
Methods: A total of 22 pts were consecutively treated with CMI and compared to 30 
successive pts treated with Pixel. Only single, de novo lesions <14mm in length, in native 
vessels of 2.0-2.5mm in diameter were included. Primary goal was the comparison of QCA 
lumen loss (LL) and IVUS neointimal (NIH) formation between the 2 groups at 6 months.
RESULTS: Baseline clinical features were similar for both groups. The CMI group had 
smaller vessels. The table displays QCA and IVUS results at 6 months. Notably, IVUS 
demonstrated that the CMI increased its size along the months while Pixel had no 
significant augment. Binary restenosis happened in 4 pts in the CMI group vs 10 in the 
Pixel (p=0.34).
Conclusion: The CMI showed enthusiastic preliminary results with superior reduction 
in LL and NIH compared to Pixel in SV. The clinical impact of these findings should be 
assessed in a larger cohort of patients.
CardioMind™
N=22
Pixel™
N=30 P value
Reference Vessel Diameter, mm 2.20 ± 0.20 2.43 ± 0.16 <0.0001
Acute Gain, mm 1.29 ± 0.27 1.68 ± 0.22 <0.001
In-Stent Late Lumen Loss, mm 0.73 ± 0.57 1.11 ± 0.72 0.04
IVUS % NIH Obstruction 33.7 ± 8.9 39.18 ± 24.3 0.02
IVUS % Chronic Stent Expansion 13% 2.5% 0.03
1:30 p.m.
2902-10 A Novel Noninvasive Digital Arterial Pulse Wave 
Analysis During Deep Breathing as an Indicator of 
Significant Coronary Artery Disease: A Two-centers 
Study
Amos Katz, David Brosh, Yosi Blaer, Abid Assali, Jamal Jafari, Yan Orlov, Ran 
Kornowski, Barzilai Medical Center, Ashkelon, Israel, Rabin Medical Center, Petach 
Tiqva, Israel
Background: Previous studies have indicated that fluctuations in pulse wave amplitude 
(PWA) might be a predictor of coronary artery disease (CAD). We analyzed the respiratory 
modulation spectral response (RMR) of the PWA during deep breathing at a frequency 
of 0.1 Hz by a novel Cardiometer® device, utilizing a photo plethysmograph sensor, 
attached to the patient’s finger and proprietary software. This noninvasive simple test was 
evaluated as an indicator of significant CAD in two academic medical centers.
Methods: RMR results of 221 consecutive pts (mean age 63.7 ± 11.7 years, 75% male), 
referred for coronary angiography, (119 pts in Rabin MC and 102 pts in Barzilai MC), were 
compared with coronary angiography results. Patients with luminal stenosis of ≥ 70%, or 
left main stenosis ≥ 50% were classified significant CAD. RMR testing was performed 
in recovery room of catheterization laboratory prior to coronary angiography. RMR was 
analyzed after baseline 20 seconds spontaneous breathing, followed by 70 seconds of 
guided deep breathing at 0.1 Hz. RMR testing was repeated post procedure in 175 pts 
following PCI or diagnostic catheterization.
Results: The RMR (range 78% [best] to 0% [worst]) was significantly lower in pts 
with significant CAD (n=131) vs. pts with non-significant CAD (n=90) (18.16±18.79 vs. 
39.07±18.36, P<0.001). Improvement in post procedure RMR was significantly higher in 
pts with significant CAD who had undergone successful PCI compared to pts who had only 
diagnostic catheterization only (22.50± 22.74 vs. 1.80 ± 18.65, P<0.001). RMR was lower 
in the subgroup of pts (29/192) with recent MI (17.34 vs. 28.08, P=0.011). Using receiver 
operating characteristic curve (ROC) analysis, we identified RMR<29% (sensitivity=0.80, 
specificity=0.77; positive and negative predictive values: 0.83, 0.73, respectively) to be 
the optimal cut-off value for predicting significant CAD. Clinical characteristics and the 
RMR results were similar in the two centers.
Conclusions: The novel digital PWA analysis test during deep breathing using the 
Cardiometer device is a simple, non-invasive bedside or office based test to detect 
significant CAD and to monitor patients with CAD post PCI.
1:36 p.m.
2902-11 Improved Endothelial Coverage of Drug-Eluting Stents 
When Overlapped With an Endothelial Progenitor Cell 
Capture Stent
Gaku Nakazawa, Frank D. Kolodgie, Sherry Parker, Meg Yoklavich, Renu Virmani, 
CVPath Institute, Inc, Gaithersburg, MD, Orbus Neich Medical, Inc., Fort Lauderdale, FL
Background: At autopsy, drug-eluting stent (DES) exhibit delayed endothelial regrowth, 
potentially increasing the risk for late in-stent thrombosis. Moreover, animal studies of 
overlapping DES show delayed arterial healing and endothelial coverage relative to bare 
metal stents. One strategy for improving endothelial coverage involves a pro-healing 
approach where an anti-CD34 endothelial progenitor cell capturing stent (EPCS) is 
deployed in combination with DES.
Methods: Combination stent pairs (n=24) to include EPCS/EPCS, EPCS/sirolimus-
eluting stent (SES), or SES/SES were implanted in swine coronary arteries for 14- or 28-
days. After harvest, 14-day stents were bisected lengthwise and processed for scanning 
electron microscopy and whole mount immunostaining with the endothelial marker CD31/
PECAM. Vascular response was assessed by light microscopy in 28-day stents.
Results: At regions of overlap, combination EPCS/SES showed significantly greater 
endothelial coverage (82±11) compared with SES/SES (53±7, p=0.0027) (Figure). 
Corresponding CD31 staining showed improved endothelial integrity in combination 
EPCS/SES versus SES/SES with a greater percentage of localized staining at cell 
margins. At 28 days, however, combination EPCS/SES or SES/SES showed delayed 
healing with persistent fibrin and inflammation.
Conclusions: Endothelial progenitor cell capture stents present a novel approach to 
improve surface re-endothelialization of DES at sites of overlap. 
1:42 p.m.
2902-12 Coronary Plaque Composition Over the Entire Lesion, 
Not at the Minimal Lumen Site, Is Associated With 
Coronary Plaque Rupture or Ulceration
Jang-Ho Bae, Taek-Geun Kwon, Dae-Woo Hyun, Charanjit S. Rihal, Amir Lerman, 
Konyang University Hospital, Daejeon, South Korea
Background: Vulnerable plaque predisposing to plaque rupture is characterized by high 
lipid content, large inflammatory cells, and thin fibrous cap. We sought to evaluate in vivo 
tissue characterization of coronary plaque with rupture or ulceration (PRU).
Methods: Study subjects consisted of 162 consecutive patients (mean 60.1±11.9 years 
old, 119 males) who were underwent intravascular ultrasound-virtual histology (IVUS-VH) 
examination.
Results: Patients with PRU (n=68, mean 59.5 years old, 52 males) had higher 
incidence of acute coronary syndrome (89.7% vs. 20.2%, p<0.001), higher troponin-I 
level (13.7±10.1ng/mL vs. 0.7±3.4ng/mL, p<0.001), higher high sensitivity C-reactive 
protein level (0.37±0.4mg/dL vs. 0.21±0.3mg/dL, p=0.004), and lower ejection fraction 
(57.4±10.9% vs. 63.9±10.7%, p<0.001) than those without PRU (n=94, 60.6 years old, 67 
males). Patients with PRU had larger lumen (152.5±89.8mm3 vs. 113.8±55.6mm3, p=0.001), 
vessel (390.8±227.3mm3 vs. 274.0±158.8mm3, p<0.001), plaque (237.6±143.7mm3 
vs. 161.4±111.6mm3, p<0.001), fibrous (95.7±66.8mm3 vs. 59.2±52.6mm3, p<0.001), 
fibrofatty (25.2±25.3mm3 vs. 15.0±19.6mm3, p=0.005), dense calcified (11.4±12.4mm3 
vs. 7.7±7.6mm3, p=0.022), and necrotic core volume (27.7±24.5mm3 vs. 17.0±15.3mm3, 
p=0.001) over the entire lesion length than those without PRU. At the minimal lumen site, 
patients with PRU had larger vessel (17.6±5.6mm2 vs. 13.7±5.0mm2, p<0.001), plaque 
(13.6±5.4mm2 vs. 9.8±4.4mm2, p<0.001), fibrous (6.1±3.3mm2 vs. 4.1±2.5mm2, p<0.001), 
fibrofatty (1.9±2.2mm2 vs. 1.1±1.1mm2, p=0.002), necrotic core area (1.7±1.2mm2 vs. 
1.1±0.9mm2, p=0.002), and remodeling index (1.01±0.2 vs. 0.9±0.2mm2, p=0.003). 
PRU was associated with vessel volume (β=1.107, p=0.035), plaque volume (β=-2.743, 
p=0.011), fibrous volume (β=1.022, p=0.021), fibrofatty volume (β=0.522, p=0.008), 
necrotic core volume (β=0.684, p=0.005), and remodeling index (β=0.168, p=0.031).
Conclusions: Coronary plaque composition over the entire lesion, not at the minimal 
lumen site, is associated with coronary plaque rupture or ulceration.
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2902-13 Coronary Flow Velocity Pattern Immediately After 
Percutaneous Coronary Intervention Predicts Left 
Ventricular Remodeling in Patients With Acute 
Myocardial Infarction Who Achieve TIMI Grade 3 
Reperfusion
Atsushi Yamamuro, Shuichiro Kaji, Koichi Tamita, Minako Katayama, Makoto Kinoshita, 
Natsuhiko Ehara, Tomoyuki Oda, Takeshi Kitai, Takafumi Yamane, Tomoko Tani, Kazuaki 
Tanabe, Shigefumi Morioka, Yasuki Kihara, Kobe General Hospital, Kobe, Japan
Background: Studies using Doppler guidewires have shown that coronary flow velocity 
(CFV) pattern in recanalized infracted arteries predicts recovery of regional left ventricular 
(LV) function, predicts in-hospital complications, and predicts long-term cardiac events. 
However, the relationship between the CFV pattern after reperfusion and serial changes 
in LV volumes is not clear. We postulated that quantitative CFV measurement immediately 
after successful percutaneous coronary intervention (PCI) might be associated with the LV 
remodeling. To test this hypothesis, we prospectively analyzed LV remodeling according 
to CFV parameters measured by Doppler guidewires in patients with acute myocardial 
infarction (AMI) achieving TIMI 3 flow.
Methods: Consecutive 211 patients with first-time anterior AMI underwent successful 
PCI (<50% residual stenosis with TIMI flow grade 2-3) and coronary flow measurement 
with Doppler guidewires. The CFV spectrum provided the following parameters: time-
averaged peak velocity (cm/s, APV), systolic peak velocity (cm/s, SPV), and diastolic 
deceleration time (ms, DDT). The left ventriculograms, done immediately after PCI and 6 
months after the infarction, were analyzed to measure the LV end-diastolic volume index 
and LV end-systolic volume index. LV remodeling was defined as an increase in end-
diastolic volume index ≥20%.
Result: Doppler velocimetry data showed significantly lower APV (21±7 versus 26±11 
cm/s; P=0.004), lower SPV (-22±7 versus 6±23 cm/s; P<0.001), and shorter DDT 
(368±180 versus 691±193 cm/s; P<0.001) in the LV remodeling group compared with the 
no LV remodeling group. DDT and SPV correlated to the LV end-diastolic volume index 
obtained 6 months after AMI (r= -0.78; P<0.001 and r= -0.67; P<0.001, respectively). 
Even among patients achieving TIMI grade 3 flow after PCI, DDT and SPV correlated 
to the LV end-diastolic volume index obtained 6 months after AMI (r= -0.76; P<0.001 
and r= -0.63; P<0.001, respectively). Conclusions: The CFV pattern immediately after 
successful PCI appears to be an accurate predictor of LV remodeling even for patients 
with anterior AMI achieving TIMI grade 3 reperfusion.
1:54 p.m.
2902-14 Comparison the Efficacy Between the Intracoronary 
Continuous Infusion Method and the Intravenous 
Continuous Infusion Method of Adenosine to Induce 
the Maximal Hyperemia for Fractional Flow Reserve 
Measurement
Myeong-Ho Yoon, Seung-Jea Tahk, Hong-Seok Lim, Seong-ill Woo, Hyeong-Mo Yang, 
Un-Jung Choi, Jung-Won Hwang, Soo-Jin Kang, Byoung-Joo Choi, So-Yeon Choi, Gyo-
Seung Hwang, Joon-Han Shin, Ajou University School of Medicine, Suwon, South Korea
Background:Inducing steady-state and maximal coronary hyperemia without adverse 
effects is essential to measure the fractional flow reserve (FFR). We compared the efficacy 
between the method of intracoronary (IC) bolus infusion (ICB), the method of intravenous 
continuous infusion (IVC) and the method of IC continuous infusion (ICC) of adenosine 
during measuring the FFR, which was newly developed for inducing hyperemia in our 
laboratory without additional procedure.
Methods:In 21 patients with 22 intermediate lesion, hyperemia was induced successively 
by ICB method (48 μg in LCA, 36 μg in RCA), and IVC method (140 μg/min/kg) via femoral 
vein. After completion of IVC method, An IC microcatheter (ProgreatTM Microcatheter 
System, Terumo, Japan) was advanced and the tip of microcatheter was positioned at the 
coronary ostium. During measuring the FFR, ICC of adenosine via the microcatheter was 
performed with different infusion rate (60, 120, 180, 240, 300, 360 μg/min).
Results:During ICC method, the proximal coronary pressure has no significant change 
between baseline and during infusion of adenosine. The FFR measured by IVC method 
was lower than that of ICB method (0.756 ± 0.104 vs. 0.779 ± 0.086, p=0.008). Chest pain 
or AV block were occurred in five patients during IVC method. The FFRs induced by ICC 
method with 180, 240, 300, 360 μg/min were significantly lower than that of IVC method 
(0.732±0.112, vs 0.756±0.104, p=0.005; 0.727±0.112, p<0.001; 0.720±0.110, p<0.001; 
0.716±0.116, p<0.001, respectively) without adverse complications and keeping steady-
state hyperemia during ICC of adenosine. Times to inducing optimal hyperemia (90% of 
maximal hyperemia) by ICC method was more rapid than that of IVC method with 60, 
120, 180, 240, 300, 360 μg/min (45±26 vs. 76±38 sec, p=0.006; 24±12, p<0.001; 19±7, 
p<0.001; 17±7, p<0.001; 16±6, p<0.001; 16±8, p<0.001, respectively). Five patients were 
changed the functional significance of coronary lesion by ICC method, which were not 
significant by IVC method.
Conclusions:The ICC method is more effective regarding the efficacy of inducing stead-
state hyperemia without additional procedure and adverse complications compare to the 
IVC method.
2:00 p.m.
2902-15 IVUS-Guided Unprotected Left Main Coronary 
Intervention: Transit of Optimal Criteria to Predict 
Target Lesion Revascularization from Bare-Metal Stent 
to Drug-Eluting Stent 
Myeong-Ki Hong, Chang-Bum Park, Won-Jang Kim, Jong-Pil Park, Jeong-Woo Lee, 
Jae Hyoung Park, Gyung-Jung Kim, Duk-Woo Park, Seung-Whan Lee, Young-Hak Kim, 
Cheol Whan Lee, Jae-Joong Kim, Seong-Wook Park, Seung-Jung Park, Asan Medical 
Center, seoul, South Korea
We evaluated optimal intravascular ultrasound (IVUS) criteria to predict target lesion 
revascularization (TLR) after percutaneous coronary stenting for treatment of left 
main coronary artery (LMCA) lesions. From 1998 to 2006, IVUS-guided stenting for 
unprotected LMCA lesions was performed in 444 patients. Drug-eluting stent (DES) and 
bare-metal stent (BMS) were used in 297 and 147 lesions, respectively. Bifurcation and 
non-bifurcation lesions were 252 and 192 lesions, respectively. Clinical follow-up data 
were available in all patients. TLR was performed in 47 lesions (10.6%; 18.4% in BMS and 
6.7% in DES). Six-month follow-up angiogram was performed in 349 lesions (79% follow-
up rate) and angiographic restenosis rate was 16.6% (58/349). By multivariate logistic 
regression analysis, independent predictors for TLR in overall patients were use of BMS 
(p<0.001, OR=4.528, 95% CI: 2.313-8.865) and bifurcation lesion (p=0.002, OR=3.050, 
95% CI=1.494-6.226). Post-stent IVUS findings in sub-group analysis were shown in 
Table. The independent predictor for TLR by multivariate logistic regression analysis 
were post-stent area in BMS subgroup (p=0.014, OR=0.812, 95% CI=0.688-0.959) 
and bifurcation lesions in DES subgroup (p=0.037, OR=4.850, 95% CI=1.120-21.340). 
Sensitivity and specificity curves showed that optimal minimal stent area for prediction 
of TLR was 10.1 mm2 in BMS subgroup and 8.7 mm2 in DES subgroup. In conclusion, 
the independent predictors for TLR in unprotected LMCA stenting were IVUS-measured 
minimal stent area in BMS subgroup and anatomical location (regardless of IVUS 
parameter) in DES subgroup.
Table. Post-stent IVUS findings. 
BMS DES
TLR Yes (n=27) No (n=120) p Yes (n=20) No (n=277) p
Distal Ref. EEM area 
(mm2) 16.1±4.1 19.5±12.8 0.16 15.0±3.9 15.9±3.8 0.3
Distal Ref. lumen area 10.1±2.9 11.4±3.2 0.042 9.0±2.3 9.5±2.5 0.4
Lesion stent area 10.2±2.2 11.7±2.8 0.011 10.5±3.4 10.5±2.1 0.9
Proximal Ref. EEM area 23.7±5.9 21.0±5.3 0.3 15.6±0.1 19.7±3.7 0.19
Proximal Ref. lumen area 13.4±4.9 13.9±4.6 0.8 10.6±1.0 12.4±3.0 0.4
2:06 p.m.
2902-16 A Critical Intravascular Ultrasound Appraisal of the 
Angiographic Classification of Bifurcation Lesions: 
Where Is the Plaque Really Located?
Carlos R. Oviedo, Akiko Maehara, Gary S. Mintz, Jian Liu, Junqing Yang, Kenichi Tsujita, 
Takashi Kubo, Hiroshi Doi, Celia Castellanos, Alexandra J. Lansky, Roxana Mehran, 
George D. Dangas, Jeffrey W. Moses, Martin B. Leon, Gregg W. Stone, Cardiovascular 
Research Foundation, New York, NY
The Duke Classification of bifurcation lesions describes the location and severity of 
stenoses in the main vessel and side branch (Figure). But this classification has never 
been validated pathologically; and pathologic and intravascular ultrasound (IVUS) studies 
have shown that the flow divider is almost always spared in bifurcation lesions. Methods: 
We reviewed 73 angiograms of distal left main (LM), left anterior descending (LAD) 
and left circumflex (LCX) lesions with pre-intervention IVUS of both the LAD and LCX 
as well the LM. The Duke Classification was compared to the distribution of significant 
plaque (plaque burden >40%) determined by IVUS. RESULTS: Of 73 patients, 95% had 
abnormal IVUS findings (1 or more cross-section with >40% plaque burden) versus 
64% by the Duke Classification (diameter stenosis >50%). Angiography suggested that 
the carina was involved in 61%; however, IVUS showed that the carina was spared in 
all 73 pts (Figure). Compared to IVUS assessment of plaque distribution, angiography 
was concordant in 53% of segments. Unlike angiography, IVUS showed that bifurcation 
disease was rarely focal. Continuous plaque from the LM into the proximal LAD was seen 
55%, from the LM into the LCX was seen in 21%, and into both in 11%. Plaque localized 
to either the LAD or LCX ostium and not involving the distal LM was seen in only 18%. 
Conclusion: The angiographic classification of bifurcation lesions is rarely accurate. IVUS 
studies show that the carina is always spared and that the disease is rarely focal.
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2902-17 Comparison of IVUS Findings Between Arterial and 
Venous Grafts in Patients With Coronary Artery Bypass 
Surgery
Sung Yun Lee, Gary S. Mintz, Seok-Yeon Kim, Teruo Okabe, Bongryeol Lee, Young Joon 
Hong, Augusto D. Pichard, Lowell F. Satler, Ron Waksman, Kenneth M. Kent, William 
O. Suddath, Neil J. Weissman, Cardiovascular Research Institute/Medstar Research 
Institute, Washington Hospital Center, Washington, DC, Cardiovascular Research 
Foundation, New York, NY
Background: This study was designed to use intravascular ultrasound (IVUS) to define 
the mechanisms of graft failure comparing arterial vs. saphenous vein grafts (SVG).
Methods: We compared pre-intervention IVUS findings in 20 patients with arterial grafts 
(12 left internal mammary artery, 3 right left internal mammary artery, 5 radial artery) vs. 
41 patients with SVGs; all had significant de novo lesions.
Results: Most lesions were located in ostium (32.8%) and mid-shaft (24.6%) of the graft. 
Ostial lesions in arterial graft were 7/20 (35%), in SVG 13/41 ( 31.7%), there was no 
difference in incidence of ostial lesions between two groups(p=0.509). There was no 
significant difference in graft age (5.9±1.9 vs 7.0±2.6 yrs, p=0.10) or other risk factors 
including diabetes mellitus (60% vs 58.5 %, p=0.6) except patients with venous grafts 
were older (56.4±5.4 vs 61.4±7.0 yrs, p=0.047). In diseased SVGs reference vessel area, 
lesion site vessel area, lesion site lumen area, minimal lumen diameter, plaque area, 
and plaque burden were significant greater; and calcification was more common (Table). 
Positive remodeling was more common in SVGs while negative remodeling was present 
in almost 80% of arterial grafts. Plaque rupture (10.0% vs. 24.4%, p=0.16) and a lobulated 
mass (10.0% vs. 22%, p=0.2) were similar between the two groups.
Conclusions: SVG failure is associated with positive remodeling and large plaque burden 
while arterial graft failure is associated with negative remodeling and modest amounts of 
plaque. This indicates fundamentally different pathophysiologic mechanisms of venous 
and arterial conduit failure.
Arterial graft(n=20) Venous graft(n= 41) p value
Reference vessel area ( mm2 ) 6.57 ± 3.17 19.33 ± 7.34 <0.001
Lesion vessel area ( mm2 ) 5.56 ± 2.77 19.72 ± 7.82 <0.001
Lesion lumen area ( mm2 ) 1.85 ± 0.60 3.12 ± 1.41 0.001
Lesion plaque area ( mm2 ) 3.81 ± 2.56 16.54 ± 7.50 <0.001
Lesion plaque burden % 64.0 ± 13.2 81.9 ± 9.3 <0.001
Remodeling index 0.80 ± 0.17 1.05 ± 0.23 <0.001
Positive remodeling (RI >1.05) 5 % 43.8 % 0.002
Lesion calcium 23.5 % 76.2 % 0.005
2:18 p.m.
2902-18 Association of Coronary Plaque Characteristics by 
Virtual HistologyTM Intravascular Ultrasound and 
Coronary Temperature
Yoshinori Miyamoto, Hiroyuki Okura, Teruyoshi Kume, Ryotaro Yamada, Koichiro 
Imai, Eiji Toyota, Yoji Neishi, Nozomi Watanabe, Takahiro Kawamoto, Kiyoshi Yoshida, 
Kawasaki Medical School, Kurashiki, Japan
Background:Coronary temperature has been shown to be elevated in culprit lesions 
(CL) of angina pectoris (AP) patients. The purpose of this study was to investigate 
the correlation between plaque characteristics of the CL and coronary temperature in 
patients with AP.
Methods:19 patients with AP were enrolled. Plaque characteristics were assessed by 
Virtual HistologyTM intravascular ultrasound (VH-IVUS). Coronary temperature difference 
(ΔT) between the CL and the proximal vessel were measured by Pressure wire. After 
measurement of distal coronary pressure and coronary temperature, the following tissue 
types of atherosclerotic plaque were evaluated by VH-IVUS: fibrotic, fibro-fatty, dense 
calcium and necrotic core.
Results:Mean ΔT was 0.03 ± 0.03 °C. Patients were divided into the two groups, high ΔT 
group (ΔT ≥ 0.03 °C, n = 10) and low ΔT group (ΔT < 0.03 °C, n = 9). By VH-IVUS, plaque 
characteristics did not differ between the two groups, except for the higher percent dense 
calcium area in the low ΔT group than in the high ΔT group (9.0 ± 4.8 vs 3.2 ± 2.9 %, 
p = 0.005). There was a significant negative correlation between ΔT and percent dense 
calcium area (R = -0.54, p = 0.02).
Conclusions:Coronary temperature difference was lower in coronary plaque with dense 
calcium. Calcified coronary plaque may be more stable in patients with AP. 
2:24 p.m.
2902-19 High-Risk Lipid Profile Is Related to the Ratio of 
Necrotic Core to Calcification in Human Coronary 
Arteries: Results From the Prospective, Multicenter VH-
IVUS Registry
Eduardo Missel, Gary S. Mintz, Akiko Maehara, Sinan Biro, Celia Castellanos, Ryan K. Kaple, 
George Dangas, Jeffrey Moses, Gregg W. Stone, Martin B. Leon, Columbia University Medical 
Center, New York, NY, Cardiovascular Research Foundation, New York, NY
Background: Serum cholesterol levels are prognostic factors in the setting of coronary 
heart disease (CHD). Histopathological studies show that high total cholesterol to HDL-C 
ratio (TC/HDL) is related to sudden coronary death in men; while it is well known that 
LDL-C lowering therapy reduces the rates of death and acute myocardial infarction as 
a secondary-prevention measure. We describe the relationship between lipid profile and 
virtual histology intravascular ultrasound (VH-IVUS) findings.
Methods: We performed whole vessel VH-IVUS analyses in a consecutive series of 
473 male pts presenting CHD and measured the four basic VH-IVUS coronary plaque 
components - fibrous (FI), fibro-fatty (FF), dense calcium (DC) and necrotic core (NC) - as 
well as calculated a NC/DC ratio. 
Results: Pt age was 61±11years, with 27% current smokers and 69% with a lipid 
disorder. Among VH-IVUS parameters, the NC/DC ratio was the only parameter related 
both to the TC/HDL ratio (r=0.18, p=0.0008) and LDL-C levels (r=0.17, p=0.002); and 
it had a negative correlation with HDL-C levels (r=0.11, p=0.03). Patients with TC/HDL 
levels in the third tertile had a significantly higher NC/DC ratio when compared to patients 
in the first and second tertiles (p=0.004), and it was progressively higher according to 
LDL-C tertiles (p=0.01) (Figure).
Conclusion: In diseased coronary segments the ratio of necrotic core to calcification 
detected by VH-IVUS is related to a high-risk lipid profile, and therefore may be associated 
to a worse prognosis. 
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2903-5 Comparison of Long-term Outcomes Between Stenting 
and Bypass Surgery for the Treatment of Distal 
Unprotected Left Main Coronary Artery Disease
Young-Hak Kim, Duk-Woo Park, Seung-Whan Lee, Won-Jang Kim, Jong-Young Lee, 
Jae-Hyung Park, Gyung Jung Kim, In-Hyun Jung, Cheol Whan Lee, Myeong-Ki Hong, 
Jae-Joong Kim, Seong-Wook Park, Seung-Jung Park, MAIN-COMPARE Investigators, 
Asan Medical Center, seoul, South Korea
Background: The long-term outcome of percutaneous coronary intervention (PCI) 
versus coronary artery bypass grafting (CABG) has not been known in patients with distal 
unprotected left main coronary artery (ULMCA) disease.
Methods: Between Jan, 2000 and June, 2006, a total of 1106 patients with distal ULMCA 
stenosis were collected from 12 academic centers in Korea. Percutaneous coronary 
intervention (PCI) and coronary artery bypass grafting (CABG) were performed in 553 
patients and 553 patients, respectively.
Results: Patients with PCI showed a higher incidence of previous PCI. In contrast, 
patients with CABG had a higher incidence of peripheral vascular disease, family history 
of coronary artery disease and had lower ejection fraction and higher Euroscore and 
more presented with acute coronary syndrome. During long-term follow-up of median 32.6 
months, there was no difference of the rates for death or Q-wave myocardial infarction 
(MI). However, patients with PCI showed a significantly higher incidence of target vessel 
revascularization (TVR) than those with CABG. This trend was persistent in comparison 
between drug-eluting stents (DES) and CABG (Table).
Conclusions: There was no difference in the rates for death or Q-MI in patients with 
distal ULMCA disease after percutaneous or surgical treatment. However, PCI without 
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regard to stent type was significantly associated with target vessel revascularization than 
bypass surgery.
Table. Cumulative 3-year incidence of clinical events 
PCI
(n=553)
DES
(n=452)
CABG
(n=553)
PCI vs. CABG DES vs. CABG
P* Adjusted HR (95% CI) P*
Adjusted HR 
(95% CI)
Death 3.0% 2.4% 4.0% 0.741 0.75(0.44-1.26) 0.47
0.73
(0.40-1.35)
Q-MI 0.5% 0.3% 0.8% 0.972 1.15 (0.33-4.05) 0.40 0.60(0.12-3.05)
TVR 6.7% 5.0% 1.4% <0.001 12.17(6.21-23.831) <0.001
7.59
(3.63-15.88)
Death/
Q-MI/
TVR
9.1% 7.2% 5.5% <0.001 2.65(1.83-3.85) 0.001
2.01
(1.35-2.99)
*Log-rank P
1:06 p.m.
2903-6 Drug-eluting Stents for the Treatment of Unprotected 
Left Main Coronary Stenosis: Intermediate to Long-
term Results from a Two-center Registry
Kyung Woo Park, Keun-Ho Park, Dong-A Kwon, Dong-Hyun Choi, Jung-Won Suh, 
Hyun-Jai Cho, Hae-Young Lee, Woo-Young Chung, Tae-Jin Yeon, In-Ho Chae, Hyo-
Soo Kim, Byung-Hee Oh, Young-Bae Park, Yoon-Shik Choi, Seoul National Univeristy 
Hospital, Seoul, South Korea, Seoul National University Bundang Hospital, Seongnam, 
South Korea
Background: To evaluate the mid to long term clinical outcome of PCI for unprotected left 
main coronary artery stenosis (LMCAS), we performed a retrospective analysis of a two 
center registry from the Seoul National University Main and Bundang Hospital.
Methods: All patients with unprotected LMCAS receiving DES from Feb 2003 to Aug 
2006 were consecutively enrolled. These patients had at least 1 year of follow-up. In-
hospital and clinical outcome up to September 2007 was analyzed
Results: 170 patients with unprotected LMCAS received DES implantation. These were 
high risk patients with over 50% of the patients having multivessel involvement other 
than left main lesion, 10% with CRF, over 58% presenting as ACS, 11% receiving urgent 
procedure, and left main distal bifurcation involving lesions comprising 80% of the lesions. 
Procedure wise, Gp IIb/IIIa inhibitors were used in 9% of the cases, IABP in 11% and 
direct stenting was done in 11% of the patients. Sirolimus eluting stent was the most 
commonly used stent (71%). Within the LM bifurcation involving lesions, complex stenting 
was done in 44% of the cases (Kissing stent, crush, and T or modified T techinique: 
18.4%, 11.8%, and 13.2% respectively) and final kissing balloon inflation was performed 
in 50% of the cases. Procedural success rate was 98.8% and inhospital death rate was 
4.1%. Except for 5 patients who were lost during follow-up, 165 patients were followed for 
at least 1year and the mean duration of follow-up was 23.9±12 months. At six months, 
the cumulative CV death rate was 5.4% with TLR rate 8.3% and TVR rate 13.1%. This 
increased to 5.4%, 8.4%, and 13.9% respectively at 1year. At final follow-up, the rate 
of cumulative all cause death was 13.9%, CV death 9.1%, cumulative TLR 9.1%, and 
TVR 16.4%. The rate of stent thrombosis(ST) was 3.0% when using the ARC definite 
and probable ST classification and late or very late thrombosis occurred in only 0.6% 
of the patients.
Conclusions: PCI for LMCAS using DES showed good peri-procedural outcome with 
acceptable rates of MACE up to 2 years. However, the continued occurrence of cardiac 
death and TVR in this ‘real world all-comer’ LMCAS cohort, warrants caution and suggests 
the need for patient selection when performing PCI.
1:12 p.m.
2903-7 Influence of Distal Bifurcation Involvement on 
Long-term Clinical Events in Patients Undergoing 
Revascularization for Unprotected Left Main Disease
Ki Bae Seung, Bum-Joon Kim, Young-Hak Kim, Duk-Woo Park, Won-Jang Kim, Jong-Pil 
Park, Jeong-Woo Lee, Jong Young Lee, Seung-Whan Lee, Cheol Whan Lee, Myeong-
Ki Hong, Jae-Joong Kim, Seong-Wook Park, Seung-Jung Park, MAIN-COMPARE 
Investigators, Asan Medical Center, Seoul, South Korea
Background: Distal bifurcation involvement has been regarded as a major predictor for 
adverse clinical outcomes in patients undergoing revascularization for unprotected left 
main coronary artery (ULMCA) disease.
Methods: Between Jan, 2000 and June, 2006, a total of 2311 patients with ULMCA 
stenosis were enrolled from 12 academic institutions in Korea. Percutaneous coronary 
intervention (PCI) and coronary artery bypass grafting (CABG) were performed in 1141 
and 1170 patients, respectively.
Results: Bifurcation stenosis at ULMCA was identified in 1106 patients (50.4%). Patients 
with bifurcation stenosis had significantly higher risk clinical and procedural profiles (old 
age, male gender, history of angioplasty, myocardial infarction or stroke, hypertension, 
smoking, hyperlipidemia, unstable angina) than those without bifurcation stenosis. During 
median follow-up of 37.5 months, bifurcation involvement was not associated with long-
term morality. However, bifurcation involvement was significantly associated with increase 
of target vessel revascularization in patients undergoing PCI, not CABG (Table).
Conclusions: In patients with ULMCA disease, bifurcation disease was not related 
with an increased mortality. However, distal bifurcation involvement was associated with 
more frequent repeat revascularization in patients undergoing PCI, but not in patients 
undergoing CABG. 
Bifurcation Non-Bifurcation P
Overall(n) 1106 pts (50.4%) 1089 pts (49.6%)
Death 3.5% 3.5% 0.7
Q-MI 0.7% 0.3% 0.03
TVR 4.1% 2.8% 0.001
Death/Q-MI/TVR 7.4% 6.2% 0.015
PCI group 553 pts (49%) 576 pts (51.0%)
Death 2.9% 3.7% 0.740
Q-MI 0.5% 0.3% 0.132
TVR 6.6% 4.7% <0.001
Death/Q-MI/TVR 8.9% 8.1% 0.003
CABG group 553 pts (51.9%) 513 pts (48.1%)
Death 4.1% 3.3% 0.356
Q-MI 0.8% 0.3% 0.108
TVR 1.4% 0.8% 0.147
Death/Q-MI/TVR 5.7% 4.2% 0.145
Q-MI;Q-wave myocardial infarction, TVR;target vessel revascularization
1:18 p.m.
2903-8 Sirolimus-eluting Stent Implantation for Unprotected 
Left Main Coronary Artery Disease: One-year Outcomes 
Insights From the J-Cypher Registry
MAMORU TOYOFUKU, Yasuhiko Hayashi, Kazuaki Mitsudo, Takeshi Morimoto, Takeshi 
Kimura, on behalf of j-CYPHER Investigators, Tsuchiya General Hospital, Hiroshima, 
Japan, Kyoto University Hospital, Kyoto, Japan
Background: Recent reports have questioned the long-term safety of drug-eluting stent 
(DES). Cautious monitoring is required in patients treated with DES on unprotected 
LMCA.
Methods: Design of this registry was multi-center prospective enrollment of consecutive 
patients undergoing sirolimus-eluting stent deployment from 40 centers in Japan. From 
Aug 2004 to May 2006, 384 patients received stent for the treatment of unprotected 
LMCA disease and 330 patients (86%) achieved complete one-year follow-up. Among 
384 patients, there were 332 electively treated patients [Mean age 70 years, 15% with 
acute coronary syndrome (ACS) and 22% with heart failure] and 52 emergency patients 
(Mean age 70 years, 80% with ACS and 35% with heart failure). End points were death, 
stent thrombosis, and target lesion revascularization (TLR).
Results: Procedural successes were achieved in all patients. The one year mortality rate 
was 10.6% (35 cases, emergency 32.6%, elective 7.0%) and cardiac mortality rate was 
6.7% (22 cases, emergency 19.6%, elective 4.6%). The incidence of definite or probable 
stent thrombosis as defined by the ARC was 1.8% (6 cases) including 0.9% (3 cases) of 
angiographic confirmation. By one-year, 11.5% (38 cases) of patients experienced TLR. In 
multivariate logistic regression analysis, independent predictors of cardiac mortality were 
dialysis (odds ratio 2.4, P=0.0022) and heart failure (OR 2.1, P=0.0064). The occurrence 
of TLR was significantly related to bifurcation two stenting (OR 1.9, P=0.0048), dialysis 
(OR 2.2, P=0.0059), long stenting (>41mm)(OR 3.36, P=0.0086).
Conclusions: In our population, stenting of unprotected LMCA disease was safely 
conducted in Japan. Careful follow-up is warranted in patients with dialysis and in those 
undergoing treatment with bifurcation two stenting or long stenting.
1:24 p.m.
2903-9 Long-term Predictors of Cardiac Death After 
Unprotected Left Main Stenting Using a Provisional 
T Stenting Strategy and Paclitaxel-eluting Stents: 
Insights From the French Left Main Taxus Registry
Thierry Lefevre, Beatriz Vaquerizo, Olivier Darremont, Marc Silvestri, Philippe Garot, 
Helen Routledge, Yves Louvard, Jean Louis Leymarie, Marie-Claude Morice, Institut 
Cardiovasculaire Paris Sud, Massy, France
Background: Although drug-eluting stents have emerged as an alternative to surgery 
(CABG) in patients (Pts) with unprotected left main (LM) disease, the predictors of cardiac 
death remain unknown.
Methods: In order to assess the long term predictors of cardiac death after LM stenting, univariate 
and multivariate analyses were performed in the French LM Taxus Registry database.
Results: In this prospective multicenter study, Pts with ULM disease were treated with 
paclitaxel eluting stents (PES) with a strategy of provisional side branch (SB) T-stenting 
in case of distal LM. 291 Pts were included, aged 69±11 yrs, 29% diabetic, 28% renal 
failure, 18% previous or recent MI, 35% acute coronary syndrome, 25% 3-vessel disease 
and Euroscore 4.8±3.4 (predicted CABG in-hospital mortality 6.4±10.5%). LM lesion was 
distal in 78% of cases, provisional SB T stenting was used in 92% (SB stented in 43% of 
cases), with final kissing balloon in 97%. Angiographic success was obtained in 99.7%. 
Two-year follow-up was obtained in 99.3%. Target vessel revascularization rate was 7.9% 
and overall mortality rate 9.3% (cardiac 5.2%). Univariate predictors of cardiac death are 
summarized in the table. By multivariate analysis, Euroscore (OR 1.19; 95% CI 1.03-1.36; 
p<0.05) and lower creatinine clearance (OR 0.96; CI 0.94-0.99, p<0.005), were the only 
independent predictors of cardiac death. 
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No cardiac death 
(274) Cardiac death (15) P value
Additive Euroscore 4.6±3.2 6.8±3.4 0.03
Logistic Euroscore, % 5.8±9.1 10.8±11.2 <0.05
Age, years 68.5±11.6 72.9±9.8 0.08
Men, % 72.6 100 0.03
LVEF, % 61.2±12.5 49.9±16.2 <0.005
Dyslipidemia, % 63.5 40.0 <0.05
Creatinine clearance, ml/min/
1.73m2 125.4±52.9 75.2±43.3 <0.005
Dialysis therapy, % 1.5 6.6 <0.05
Distal LM bifurcation, % 76.6 80.0 0.48
LM bifurcation angle T-type, % 35.7 66.6 <0.05
SB stenosis before PCI, % 43±30 64±34 <0.01
Stent 2 branches, % 41.4 66.6 <0.05
Conclusions: Unprotected LM PCI using PES with a strategy of provisional SB T stenting 
in cases of distal LM disease provides excellent acute and very good mid-term results. 
Euroscore and chronic renal failure on dialysis were the only independent predictors of 
cardiac death at 2 years’ follow-up.
1:30 p.m.
2903-10 Provisional T-stenting and Small Protrusion Technique 
for Bifurcation Lesion: Nine-month Follow-up Results
Hyeon-Cheol Gwon, Seung Min Choi, Jung Hyuk Kim, Yong Hwan Park, Joo-Yong 
Hahn, Jin Ho Choi, Seung Hyuk Choi, Sang Hoon Lee, Samsung Medical Center, 
Sungkyunkwan University School of Medicine, Seoul, South Korea
Background: T-stenting And Small Protrusion (TAP) technique may improve the long-
term result of bifurcation stenting by complete coverage of side branch ostium after main 
vessel stenting.
Methods: This study is a single center prospective registry of provisional TAP technique 
using drug eluting stent; after main vessel stenting, a side branch stent was intentionally 
pulled back into the parent stent to be sure to cover the side branch ostium. Patients with 
a bifurcation lesion with side branch > 2.3 mm by visual assessment were included. The 
indication of side branch stenting was residual stenosis > 50% or any dissection in side 
branch. Intravascular ultrasonography was performed in every case.
Results: Two hundred eleven lesions in 207 patients were included. Left main bifurcation 
was 77 lesions (37%), and left anterior descending artery 114 lesions (54%). Out of 211 
lesions, 122 lesions (58%) stented both branches using TAP technique. There was no 
cardiac event for 30 days after the procedure, except one cardiac death in 2-stent group. 
Nine-month clinical follow-up was completed in 168 patients (100% of due follow-up 
period). Cardiac death was noted 3 patients (1.8%), target lesion revascularization (TLR) 
in 5 patients (3.0%), and target vessel revascularization (TVR) in 6 patients (3.6%). Nine-
month angiographic follow-up was completed in 119 lesions in 118 patients. Restenosis 
was noted in 6 lesions (5.0%) in main vessel, in 8 lesions (6.7%) in side branch, and 11 
lesions (9.2%) in any branch. Restenosis rate was not significantly different between 1-
stent and 2-stent groups both in main vessel and side branch.
Conclusions: Provisional TAP technique is safe and effective strategy to treat coronary 
bifurcation lesion. Acceptable result was achieved both in 1-stent and 2-stent groups.
Nine-month clinical results (*Definite and probable stent thrombosis by ARC definition)
Cardiac death TLR TVR Stent thrombosis*
1-stent (N=71) 1(1.4%) 1(1.4%) 2(2.8%) 1(1.4%)
2-stent (N=97) 2(2.1%) 4(4.1%) 4(4.1%) 2(2.1%)
p-value 1.0 0.40 1.0 1.0
1:36 p.m.
2903-11 Efficacy of Directional Coronary Atherectomy Prior to 
Sirolimus-eluting Stent Implantation in the Treatment 
of the Lesion of Unprotected Left Main Coronary Artery 
Involving Bifurcation Stenosis
Nobuyoshi Tanaka, Yoshihisa Kinoshita, Kenya Nasu, Masashi Kimura, Mariko Ehara, 
Etsuo Tsuchikane, Keiko Asakura, Mitsuyasu Terashima, Tetsuo Matsubara, Yasushi 
Asakura, Osamu Katoh, Takahiko Suzuki, Toyohashi Heart Center, Toyohashi, Japan
Background: There are several reports regarding percutaneous revasculization of 
unprotected left main coronary artery (ULMCA) involving bifurcation stenosis using 
sirolimus-eluting stent (SES), but the concern about restenosis of left circumflex artery 
(LCx) is not still resolved.This study was performed to evaluate the efficacy of directional 
coronary atherectomy (DCA) prior to SES implantation for ULMCA involving bifurcation 
stenosis.
Methods: Target population consisted of 101 patients with ULMCA bifurcation stenosis 
who underwent single SES implantation with or without DCA (DCA group; n=41, non-DCA 
group; n=60). Quantitative Coronary Angiographic (QCA) analysis of the lesion, stented 
segments and the orifice of LCx were performed at baseline, post-intervention, and 9-
month follow-up. Measure adverse cardiac event (MACE) free rate, including cardiac 
death, myocardial infarction, and target vessel revascularization was also assessed at 15 
months after SES implantation.
Results: There were no major complications in the DCA group, whereas LCx occlusion 
occurred in one case in the non-DCA group. Baseline angiographic characteristics of 
LMCA lesion were similar on QCA analysis in the 2 groups, but percent diameter stenosis 
(%DS) of LCx before treatment was larger in the DCA group than in the non-DCA group 
(36.8±21.5% vs. 26.9±19.2%, p=0.029). Nevertheless, %DS of LCx after treatment was 
smaller in the DCA group, compared to the non-DCA group (19.2±13.1% vs. 28.3±22.7%, 
p=0.034), and this difference was maintained until 9-month follow-up (20.8±12.3% vs. 
31.9±21.4%, p=0.007). Angiographic restenosis rate for LMCA was similar for both groups 
(DCA group; 2.7% vs. non DCA group; 6.1%, p=0.472), but those for the LCx were lower 
in the DCA group than the non-DCA group (0% vs. 10.2%, p=0.048). At 15-month MACE 
free rate was 97.5% in the DCA group and 89.8% in the non-DCA group (p=0.148).
Conclusions: On the treatment of ULMCA bifurcation lesions, plaque debulking with DCA 
prior to SES implantation was safe with a high procedural success rate. Furthermore, this 
strategy has been accompanied with a low incidence of MACE during long-term follow-up 
and lower restenosis rate of the LCx.
1:42 p.m.
2903-12 Drug-Eluting Stents for the Treatment of Left Main 
Coronary Artery Disease with Sirolimus, Paclitaxel, 
Zotarolimus, Tacrolimus-Eluting Stent and EPC Capture 
Stent: Multicenter Registry in Asia
Sunao Nakamura, Shotaro Nakamura, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan 
Udayachalerm, Damras Tresukosol, Sudaratana Tansuphaswadikul, New Tokyo Hospital, 
Chiba, Japan, Konyang University Hospital, Daejeon, South Korea
Aim: The aim of this study is to compare the safety, efficacy and durability of Sirolimus 
(SES), Paclitaxel (PES), Zotarolimus (ZES), Tacrolimus-eluting stent (TES) and EPC 
capture stent (ECS) on the outcome of patients with left main coronary arteries (LMT) 
stenosis. Methods: A prospective analysis of 628 patients with 628 LMT stenosis (248 
SES, 172 PES, 104 ZES, 62 TES, 42 ECS) in five high volume Asian centers after 
successful stenting in LMT stenosis was performed. The study endpoints were 30 days 
and 9 months major adverse cardiac events (MACE), 9 months angiographic restenosis 
and target lesion revascularization (TLR) in those 4 groups and 24 months MACE in 
SES and PES groups. Results: See table for clinical results. Conclusion: The use of 
drug-eluting stents in patients with LMT stenosis was safe with low acute complication. 
Patients treated with SES showed lesser rate of restenosis compared with other drug-
eluting stents. 
SES PES ZES TES ECS
Number of patients 248 172 104 62 42
Procedural success (%) 100 100 100 100 100
MACE at 30 days (%) 0 0 0 0 0
Proximal reference diameter 
(mean: mm) 3.6 3.5 3.5 3.6 3.7
Stenting procedure: culotte/
single/crush 75/87/86 52/40/80 36/39/29 24/30/8 10/29/3
Minimum lumen diameter post 
procedure (mean: mm) 3.5 3.5 3.3 3.4 3.5
Minimum lumen diameter at 9 
months (mean: mm) 3.4 3.0 2.9 3.0 3.1
Restenosis rate at 9 months (%) 7.3* 9.9 16.3 16.2 16.7
TLR at 9 months (%) 6.0* 8.7 14.4 14.5 14.3
MACE at 2 years (%) 6.0 8.7 - - -
*p<0.05 vs ZES, TES
1:48 p.m.
2903-13 Long-Term Clinical Results After Percutaneus 
Treatment of Distal Left Main Stenosis Using T-Stenting 
or Stenting of the Main Branch With Kissing Balloon of 
the Side Branch
Miroslaw FERENC, Heinz-Joachim Buettner, Hans-Peter Bestehorn, Michael Gick, 
Klaus Werner, Juergen Allgeier, Jan Minners, Piotr Kuebler, Franz-Josef Neumann, 
Heart Center, Bad Krozingen, Germany
Background: Percutaneus treatment of distal left main stenosis has become an 
alternative to CABG, particularly in patients with high surgical risk. There is still a lack of 
long term data regarding efficacy and safety of different stenting strategies (one or two 
stents) in PCI of distal left main stenosis.
Methods: Our registry of consecutive patients includes 140 patients with distal left main 
stenosis, which was unprotected in 102 patients (72.9 %). Here we present 3-year clinical 
follow-up data. We treated 65 patients with single stent technique including final kissing 
dilatation for the side branch and 75 patients with two stents using T-stenting. The majority 
of patients (90.7 %) received drug-eluting stents.
Results: After 3-year follow-up 84.3 % of the patients were still alive. The 3-year incidence 
of death and myocardial infarction was 20.7 % and that of target lesion revascularization 
(TLR) 32.9 %. The 2 groups with single or T-stenting were comparable with respect to 
pertinent baseline clinical characteristics. After three years, TLR was performed in 10.8 
% of patients treated with a single stent and 30.7 % of patients who underwent T-stenting 
(p=0.003). The combined endpoint of death and myocardial infarction (MI) as marker for 
safety was reached by 23.1 % of patients in the single stent group and 18.7 % in the 
T-stenting group (p=0.638). We found a higher 3-year mortality after single stenting as 
compared with T-stenting, which did not reach statistical significance (20 % vs. 12 %; 
p=0.268).
Conclusions: Left main bifurcation lesions that can be managed with the single stent 
strategy have a lower restenosis rate than lesions treated with T-stenting. Compared with 
single stenting, T-stenting does not increase the 3-year risk of death and MI.
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2903-14 Impact of Kissing Balloon After Single Stent 
Deployment for Bifurcation Lesions
Kenya Nasu, Etsuo Tsuchikane, Osamu Katoh, Hiroshi Fujita, Masashi Kimura, Mariko 
Ehara, Yoshihisa Kinoshita, Keiko Asakura, Yasushi Asakura, Tetsuo Matsubara, 
Mitsuyasu Terashima, Takahiko Suzuki, Toyohashi Heart Center, Toyohashi, Aich, Japan
Background: No general agreement has yet been reached on a definitive technique for 
stent implantation in bifurcation lesions. Single stenting with kissing balloon (KB) is one 
treatment option for bifurcation lesions. However, there is little data available regarding 
the effect of KB after single stenting. The aim of this study was to evaluate the impact of 
KB after single stenting for bifurcation lesions.
Methods: A total of 329 bifurcation lesions (side branch diameter > 2.0mm) were treated 
with a single sirolimus-eluting stent. We excluded 70 lesions with flow-delay or occlusion 
after stenting in the side branch. Immediate and long-term clinical results at 9 months 
were evaluated.
Results: KB after stenting was performed in 174 lesions and 85 lesions were treated 
without KB. Although residual stenosis after stenting in the ‘Without KB’ group was higher 
than that in the ‘With KB’ group, major adverse cardiac events (MACE) and target lesion 
revascularization (TLR) rates were not different between the two groups (Table).
Conclusions: KB was not associated with a long-term clinical advantage in lesions with 
good blood flow of the side branch after stenting.
Immediate and long-term clinical results
With kissing 
balloon  
(n = 174)
Without kissing balloon 
(n = 85) p value
Kissing balloon pressure 11.8±5.2atm
Residual stenosis in side branch 
(>75% stenosis by visual estimation) 8% 45% <0.0001
MACE (Any death, MI, TLR) 8% 7% 0.78
TLR in only main branch 1.7% 1.2% >0.99
TLR in only side branch 2.3% 2.4% >0.99
TLR in main and side branches 1.7% 1.2% >0.99
2:00 p.m.
2903-15 Major Determinants for Long-Term Mortality After 
Coronary Stenting in Patients With Unprotected Left 
Main Disease
Ki Bae Seung, Bum-Joon Kim, Young-Hak Kim, Duk-Woo Park, Seung-Whan Lee, Won-
Jang Kim, Gyung Jung Kim, Jeong-Woo Lee, Jong-Pil Park, Cheol Whan Lee, Myeong-
Ki Hong, Jae-Joong Kim, Seong-Wook Park, Seung-Jung Park, MAIN-COMPARE 
Investigators, Asan Medical Center, Seoul, South Korea
Background: Data are limited about important risk factors for long-term mortality in 
patients undergoing percutaneous coronary intervention (PCI) for unprotected left main 
coronary artery (ULMCA) disease.
Methods: Between Jan, 2000 and June, 2006, a total of 1141 patients with ULMCA 
stenosis underwent coronary stenting at 12 academic institutions in Korea. Bare-metal 
stents (BMS) and drug-eluting stents (DES) were implanted in 336 and 805 patients, 
respectively.
Results: During long-term clinical follow-up (median 33.3 months, IQR 22.6-47.9), 75 
patients died with 3-year cumulative incidence of 7.1%. After multivariable Cox regression 
analysis, use of durg-eluting stent, previous congestive heart failure (CHF), chronic 
renal failure (CRF), high Euroscore (≥6), chronic obstructive lung disease (COPD), and 
average stent size were major predictors for all-cause mortality in the overall PCI patients. 
In patients treated with BMS, high Euroscore (≥6), average stent size were identified as 
independent predictors of mortality. In patients treated with DES, previous CHF, CRF, 
COPD, high Euroscore (≥6), and intravascular ultrasound guidance were major predictors 
of mortality. (Table)
Conclusions: Several clinical, lesion, or procedural characteristics were identified as 
important predictors for long-term mortality in patients undergoing PCI for ULMCA, 
showing stent-specific differences in relative weight of prognostic factors. 
HR 95% C.I. p
Overall PCI patients 
Use of drug-eluting stent 0.40 0.20-0.78 0.01
Previous congestive heart failure 2.76 1.24-6.13 0.01
Chronic renal failure 5.41 2.54-11.53 <0.001
Euroscore ≥ 6 2.79 1.56-5.04 0.001
Chronic obstructive pulmonary disease 3.04 1.13-8.19 0.03
Average stent size 0.22 0.10-0.45 <0.001
BMS Patients
Euroscore ≥ 6 3.49 1.49-8.20 0.004
Average stent size 0.14 0.05-0.35 <0.001
DES Patients
Previous congestive heart failure 2.66 1.03-6.85 0.04
Chronic renal failure 4.87 2.10-11.26 <0.001
Chronic obstructive pulmonary disease 2.93 1.00-8.53 0.05
Euroscore≥6 3.24 1.48-7.09 0.003
Intravascular ultrasound guidance 0.43 0.21-0.87 0.02
HR=hazard ratio
2:06 p.m.
2903-16 Midterm Clinical Outcomes of Sirolimus- Versus 
Paclitaxel-Eluting Stents for the Treatment of 
Bifurcation Lesions
Kang-yin Chen, Seung-Woon Rha, Zhe Jin, Yoshiyasu Minami, Jin Oh Na, Cheol Ung 
Choi, Soon Yong Suh, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, 
Dong Joo Oh, Cardiovascular Center, Korea University Guro Hospital, Seoul, South Korea
Background: Angioplasty of bifurcation lesions represents a continuing challenge. 
Although drug-eluting stent (DES) have been shown to reduce restenosis in many types 
of off-labeled lesions, however it is less known that which DES is superior, in the treatment 
of bifurcation lesions.
Method: A total of 208 patients (pts) were randomly receive either Sirolimus (SES group; 
n=160 pts, 183 lesions) or Paclitaxel (PES group, n=148 pts, 174 lesions) -eluting stents. 
PCI strategy for bifurcation lesion was mainly stent crossover, crushing stenting and 
kissing stenting. Clinical outcomes at 6 months were evaluated.
Result: The current two groups had similar baseline clinical and procedural characteristics 
except SES group had larger stent diameter (3.01±0.35 vs. 2.91±0.41, p=0.013) and 
longer stent length (26.51±5.70 vs. 24.74±6.42, p=0.007) than those of PES group. At 6 
months, the SES group had larger follow-up minimal luminal diameter (MLD), less late 
loss and trend toward less binary restenosis in the main branch (MB) than those of PES 
group. However, these two groups had similar clinical outcomes and incidence of stent 
thrombosis at 6 months (Table).
Conclusion: Sirolimus- and paclitaxel-eluting stents had similar mid-term clinical 
outcomes in the treatment of bifurcation lesions regardless of bifurcation stenting strategy 
despite the SES substantially reduced intimal hyperplasia.
Table: Angiographic and clinical outcomes at 6 months 
Variable, n (%) SES Group(n=160 pts,183 lesions)
PES Group
(n=148 pts,174 lesions) P value
MB Binary restenosis 8 (5.0) 16 (10.8) 0.057
MB follow up MLD, mm 2.68±0.68 2.13±0.90 0.001
MB Late loss, mm 0.53±0.56 0.91±0.70 0.001
Cardiac death 5 (3.1) 4 (2.7) 1.000
Total death 6 (3.8) 5 (3.4) 0.861
Q-wave MI 1 (0.6) 0 (0) 1.000
TLR 3 (1.9) 0 (0) 0.249
TVR 3 (1.9) 0 (0) 0.249
TVR-MACE 10 (6.3) 5 (3.4) 0.242
Stent thrombosis 3 (1.9) 1 (0.7) 0.624
*MB (Main Branch), MLD (Minimal luminal diameter)
2:12 p.m.
2903-17 Technique Selection and Long-Term Outcomes After 
Percutaneous Coronary Intervention of Bifurcation 
Lesions
Vladimir Dzavik, Nicholas Collins, Peter H. Seidelin, Paul Daly, Alan Barolet, Karen 
Mackie, Sanh Bui, Leonard Schwartz, University Health Network, Toronto, ON, Canada
Background: The optimal approach to percutaneous coronary intervention (PCI) 
of bifurcation lesions remains unclear, reflecting lack of long term follow up, and 
heterogeneity of lesions encountered. We sought to evaluate the long-term outcome of 
patients undergoing bifurcation PCI followed in the prospective bifurcation registry at the 
University Health Network, Toronto, Canada.
Methods: Patients undergoing bifurcation PCI between November 2003 and March 2005 
(n=527) were classified according to bifurcation technique performed as 1) main vessel 
stenting only (n=247), 2) crush or culotte stenting (n=140), 3) simultaneous kissing stents 
(SKS) or V stenting (n=18) and 4) T-stenting (n=41), with 468 procedures performed 
utilizing one of these technique groups. Results: After mean follow-up of 26.1±6.7 
months, MACE rates were: main vessel stent 22.7%, crush/culotte 17.4%, t-stent 31.7% 
and SKS/V-stent 66.7% (p<0.0001), while MACE or CCS Class ≥2 angina occurred in 
29.3%, 21.0%, 34.2% and 76.5% of patients in these groups. A low bifurcation angle was 
associated with better outcomes in the crush/culotte group and worse outcomes in the t-
stenting group. The use of the crush/culotte techniques independently predicted freedom 
from MACE and CCS Class ≥2 angina compared to main vessel only stenting.
Conclusions: The use of multiple stent techniques during bifurcation PCI, in particular 
crush/culotte and T-stenting is safe, with efficacy and MACE rates being similar to main 
vessel stenting alone. Our observations regarding the effect of lesion characteristics such 
as bifurcation angle and extent of side-branch disease on outcome underscore the need 
for an individualized approach to bifurcation PCI.
2:18 p.m.
2903-18 Clinical and Angiographic Patterns of In-Stent 
Restenosis After Drug Eluting Stenting of Unprotected 
Left Main Coronary Artery
Jacopo A. Oreglia, Petr Tousek, Guillaume Martin, Andrea Pavei, Jean Fajadet, Clinique 
Pasteur, Toulouse, France
Background: Percutaneous coronary interventions (PCI) with drug eluting stents (DES) 
could be an alternative option to coronary artery bypass graft (CABG) for unprotected left 
main coronary artery (ULMCA) stenosis. In-stent restenosis (ISR) is a common adverse 
clinical event. We describe the clinical and angiographic characteristics of patients with 
ISR in the ULMCA PCI registry of our center. Methods: 147 consecutive patients with 
stenoses of the ULMCA were electively treated with DES at our center between September 
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2002 and September 2006. Results: Mean age was 71 ± 10 years, 120 patients (82%) 
were males, 39 (27%) diabetic and 62 (42%) had renal failure (creatinine clearance < 
60mL/min). A distal ULMCA lesion was present in 94 (64%) patients. Eighty-four patients 
(57%) were electively treated with sirolimus-eluting stents, 58 (39%) with paclitaxel-eluting 
stents and 5 (4%) with zotarolimus-eluting stents. Procedural success rate was 100%. At 
long-term follow-up (FU) 17 patients had ISR. Presentation of ISR was acute coronary 
syndrome (ACS) in 7 patients (41%), silent ischemia in 5 (29.5%), while 5 ISR (29.5%) 
were found at planned angiographic control. Mean time-to-ISR was 309±248 days. Of the 
17 ISR cases, 16 (94%) had been treated for distal LMCA lesions and 1 (5.9%) for mid-
shaft LMCA stenosis. Mean stent length was 21.12±7.7 mm. The angiographic pattern 
was diffuse ISR in 2 cases (11.8%) and focal ISR in 15 cases (88.2%). ISR involved 
the LMCA mid-shaft in 2 cases (11.8%), the ostial left anterior descending artery (LAD) 
in 1 case (5.9%), the ostial left circumflex artery (LCx) in 11 cases (64.7%), the distal 
LMCA with LAD and LCx ostia in 1 case (5.9%), the distal LMCA with LCx ostium in 2 
cases (11.8%). 7 patients (41.2%) were treated with re-PCI (6 ostial LCx and 1 mid-shaft 
LMCA), 5 (29.4%) with CABG (1 LMCA-LAD-LCx, 2 LMCA-LCx, 1 mid-shaft LMCA and 
1 ostial LAD) and 5 (29.4%) with medical treatment (5 ostial LCx). Conclusion: In our 
study ISR rate was 11.6%. The most common ISR presentation was ACS and 94% of 
ISR occurred after distal LMCA stenting. Focal ISR was the most common angiographic 
pattern (88.2%). Ostial LCx was the site most frequently involved by ISR.
2:24 p.m.
2903-19 Comparison of Efficacy and Durability Between 
Sirolimus-Eluting Stent and Paclitaxel-Eluting Stent in 
Unprotected Left Main Coronary Arteries: Multicenter 
Registry in Asia
Sunao Nakamura, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan Udayachalerm, Damras 
Tresukosol, Sudaratana Tansuphaswadikul, New Tokyo Hospital, Chiba, Japan, Konyang 
University Hospital, Daejeon, South Korea
Aim: The aim of this study is to compare the safety and durability of Sirolimus-eluting stent 
(SES) and Paclitaxel-eluting stent (PES) on the outcome of patients with unprotected 
left main coronary arteries (LMT). Methods: A prospective analysis of 448 patients with 
LMT stenosis (248 SES and 200 PES) in five high volume Asian centers after successful 
stenting in LMT was performed. Lesion location of LMT was ostial 38 cases (8.5%), mid 
shaft 56 cases (12.5%) and distal 354 cases (79.0%). Complete clinical follow-up to 3 
years is being analyzed for 448 patients. Results: The baseline clinical characteristics 
between 2 groups were similar. Angiographic and clinical success were achieved in all 
patients without any major complication. At 3 years overall cardiac events of SES (7.9%) 
were lower than PES (14.3%) (p=0.045). See figure for clinical results. Conclusion: 
The use of SES and PES in patients with LMT was safe and feasible with low acute 
complication and low incidence of restenosis. SES showed lesser incidence of cardiac 
events (death, myocardial infarction, CABG and PCI compared with PES). 
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2806-3 Are DES Beneficial in Large Vessels Compared to 
BMS?: Data from the TAXUS IV and V Randomized 
Clinical Trials
David A. Cox, James Hermiller, Louis Cannon, Charles O’Shaugnessy, J.Tift Mann, 
Mark Turco, J. Greenberg, Tom Maloney, Martin Fahey, Stephen Ellis, Gregg Stone, 
Lehigh Valley Hospital, Allentown, PA, Cardiovascular Research Foundation, Columbia 
University Medical Center, New York, NY
Backgound: The risk for restenosis with BMS is decreased in large vessels, prompting 
some interventionalists to choose BMS over DES in vessels larger than 3.5mm by visual 
estimation. However, larger vessels also subtend significant amounts of myocardium and 
even small differences in clinical events between BMS and DES may be clinically relevant.
Methods: TAXUS-IV and -V were large US RCT’s comparing TAXUS (DES) to the 
EXPRESS (BMS). For this analysis, patients were divided based upon maximal device 
diameter defined as the diameter of the largest final stent or post-dilatation balloon 
utilized. Of the total 2458 patients randomized in both trials, 1528 (62.1%) had a maximal 
device diameter of <3.5mm, 655 (26.7%) > 3.5mm but < 4.0mm, and 275 (11.2%) > 
4.0mm. 1-year comparative outcomes were analyzed.
Results: 
1-year clinical events (see table below)
Conclusions: In patients with maximal device diameter of <4.0mm, TAXUS DES markedly 
reduced TLR and TVR at 1 year. Although the absolute magnitude of TLR reduction was 
smaller in vessels > 4.0mm, the relative reduction (ie 75% vs 50%) and the absolute 
reduction in MACE were maintained compared to smaller vessels. DES still offer clinical 
benefit over BMS in the treatment of vessels > over 4.0mm.
8:43 a.m.
2806-4 A Comparison of Drug-Eluting and Bare-Metal Stents 
for Saphenous Vein Graft Lesions: A Report From the 
National Heart, Lung, and Blood Institute Dynamic 
Registry
Drew E. Baldwin, Jeffrey C. Trost, J. Dawn Abbott, Helen Vlachos, Ruchira Glaser, 
Robert L. Wilensky, James N. Slater, Nirat Beohar, David O. Williams, Brown University, 
Providence, RI
Background: Recent reports have shown excessive stent thrombosis and death following 
percutaneous coronary intervention (PCI) of saphenous vein graft (SVG) lesions using 
drug-eluting stents (DES). We sought to compare DES and bare metal stents (BMS) in 
SVG patients (pts) as treated in routine practice. 
Methods: Baseline characteristics and one-year outcomes of consecutive pts who 
underwent SVG stenting in the Dynamic Registry (2001-2006) were analyzed (DES, n 
= 202 vs. BMS, n = 325).
Results: In general, baseline characteristics were similar, but DES pts were more likely 
than BMS pts to have diabetes (45.0% vs. 36.2%, p < 0.05) and prior PCI (57.7% vs. 
39.7%, p < 0.001). DES-attempted lesions had a smaller reference vessel diameter 
(3.25 vs. 3.52 mm, p < 0.001) and a longer lesion length (13.5 vs. 18.1 mm, p < 0.001). 
One-year cumulative event rates were similar (table). After adjustment using multivariate 
analysis, DES was associated with a lower risk of death/myocardial infarction (HR 0.59, 
C.I. 0.35 - 0.99, p = 0.046) and a similar risk of repeat revascularization (HR 0.71, C.I. 0.46 
- 1.08, p = 0.11) compared to BMS.
Conclusions: We found no excess hazard, and a lower rate of death/myocardial 
infarction, with the use of DES for SVG lesions in routine clinical practice. While there 
was a trend toward better outcomes with DES compared to BMS, there was no significant 
benefit in terms of repeat revascularization. Stent thrombosis was rare in both groups.
Cumulative event rates at one year, unadjusted data
All patients BMS-treated (N=325)
DES-treated 
(N=202)
p 
value
Death 7.0% 5.5% 0.50
Myocardial infarction 9.5% 6.6% 0.22
Death and myocardial infarction 15.7% 10.5% 0.08
CABG 3.1% 1.7% 0.27
Additional PTCA after discharge 19.0% 15.3% 0.28
Repeat revascularization 20.9% 17.0% 0.23
All patients, 2004-2006 (earlier data 
unavailable)
BMS-treated 
(N=70)
DES-treated 
(N=202)
p 
value
Stent thrombosis 0.0% 1.0% 0.41
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2806-5 Late and Very Late Stent Thrombosis Following Drug-
Eluting Stent Implantation in Unprotected Left Main 
Coronary Artery: A Multicenter Registry
Alaide Chieffo, Young H. Kim, Emanuele Meliga, Imad Sheiban, Michael Lee, Seung 
J. Park, Marco Valgimigli, Claudio Moretti, Seong W. Park, Dario Sillano, Matteo 
Montorfano, Valeria Magni, Azeem Latib, Duk W. Park, Giuseppe Biondi Zoccai, 
Jonathan Tobis, Patrick Serruys, Antonio Colombo, San Raffaele Hospital, Milan, Italy
Background: Some concerns have been recently raised regarding the risk of late and 
very late stent thrombosis (ST) following drug-eluting stent (DES) implantation.
Methods:All consecutive patients (pts) who had sirolimus (SES) or paclitaxel-eluting stent 
(PES) electively implanted in de novo lesions on LMCA between March 2002 and June 
2006 were included. Stent thromboses were defined according to Academic Research 
Consortium (ARC) definitions
Results: A total of 731 patients with ULMCA were electively treated in our centers with 
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PCI and DES. One-hundred and seventy-six (24.0%) pts were diabetics and 333 (45.5%) 
had unstable angina. Median and interquartile range (IQR) of Euroscore was 3.0 (2.0-
6.0); an Euroscore ≥6 was present in almost 36% of the patients. Four (0.54%) patients 
had a definite ST: 3 had early (2 acute and 1 sub-acute) and only 1 had late ST. All of 
them survived from the event. No cases of very late definite ST were recorded. 3 patients 
had probable ST. A total of 7/731 (0.95%) pts had a definite or a probable ST while on 
dual antiplatelet therapy. Possible (8 late and 12 very late) ST occurred in 20 (2.7%) 
patients. At 29.5.±13.7 months, a total of 45 (6.16%) patients died; 31 (4.2%) of cardiac 
death. Ninety-five (12.9%) patients had a TVR (83 re-PCIs and 12 CABG): 76 (10.4%) a 
TLR. Angiographic follow-up was performed in 548 pts (75%): restenosis occurred in 77 
(14%) of patients.
Conclusions:Treatment of LMCA stenosis with DES appears safe with a 0.9% incidence 
of definite and probable ST at a median follow-up of almost 3 years.
9:07 a.m.
2806-6 Angiograhic and Intravascular Ultrasound Follow-up 
of Sirolimus Eluting Stent and Paclitaxel Eluting Stent 
After Optimal Post-stent Balloon Dilation; Post-stent 
Optimal Stent Expansion Trial (POET)
Jung-Sun Kim, Jae-Youn Moon, Young-Guk Ko, Donghoon Choi, Yangsoo Jang, Woong 
Chol Kang, Taehoon Ahn, Byoung-Kuk Kim, seong Jin Oh, Dong Woon Jeon, Joo-Young 
Yang, Division of Cardiology, Yonsei University, Seoul, South Korea
Background: The aim of this study is to compare of the clinical, angiographic and 
intravascular ultrasound (IVUS) parameters with two different drug-eluting stents, 
sirolimus eluting stent (SES) and paclitaxel eluting stent (PES) after staged post-stent 
balloon inflation.
Methods:We conducted a prospective multicenter, randomized study to compare SES 
(n= 151) with PES (n=149) who underwent the elective coronary stenting for a de-novo 
lesion were included. Infarct-related lesions within 7 days were excluded. Among them, 250 
patients (M:F = 149:101, age 61.5 ± 9.2 years), and performed follow-up angiography and 
IVUS at 9 months. Stent was serially expanded with gradual increase in balloon inflation 
pressures until optimal stent expansion (OSE) defined as the criteria of MUSIC study.
Results: Baseline clinical, angiographic and IVUS characteristics of both groups showed 
no significant difference. The frequency of OSE was no different between two groups. 
[51 (33.6 %) and 50 (33.6 %) in SES and PES, p=NS]. At 9 month follow-up, the rate of 
in-stent restenosis (ISR) and neointimal volume index (neointimal volume/stent length, 
mm2) were higher in PES [ISR: 4 (3.4 %) and 17 (13.0 %), p = 0.001, neointimal volume 
index: 0.21 ± 0.37 and 1.02 ± 0.99 mm2, p < 0.001 in SES and PES]. But, OSE using 
MUSIC criteria was not significant predictor [OR: 0.9, 95 % C.I.: 0.4-2.5] of ISR and not 
related to the neointimal volume at 9 months. After controlling the clinical, angiographic 
and IVUS risk factor for ISR, PES [Odds ratio (OR): 3.9, 95 % C.I.: 1.5-10.8], presence of 
diabetes [OR: 4.1, 95 % C.I.:1.5-10.8] and > 5mm2 of minimal stent area (MSA) [OR: 0.3, 
95 % C.I.:0.1-1.0] were independent predictor for ISR. Conclusions: Although OSE was 
similar between SES and PES, PES had a significantly higher ISR and neointimal volume 
than SES at follow-up angiography. Also, diabetes and MSA were determinant factors of 
ISR, but OSE was not related with ISR and neointimal volume at 9 month follow-up.
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2806-7 Randomized Comparison between Sirolimus (Cypher), 
Sirolimus-analogous (Xience; Promus) and Paclitaxel 
(Taxus vs. Conor Costar) Eluting Stents in Coronary 
Lesions:The ABSOLUTE Trial
Enrico Romagnoli, Alaide Chieffo, Angela Ferrari, Valeria Magni, Renata Rogacka, 
Tiziana C. Aranzulla, Flavio Airoldi, Matteo Montorfano, Iassen Michev, Azeem Latib, 
Mauro Carlino, Cosmo Godino, Alfredo Castelli, Antonio Colombo, San Raffaele 
Scientific Institute, Milan, Italy
Background:Recently several drug-eluting stent (DES) have received CE mark. The 
objective of the ABSOLUTE trial was to compare the safety and efficacy of sirolimus and 
sirolimus analogous (Cypher, Xience, Promus) vs. paclitaxel eluting (Taxus vs. Conor) 
stents in unselected “real world” patients .
Methods: all consecutive patients undergoing percutaneous coronary intervention 
in our center with a clinical indication to receive a DES were randomized to Cypher, 
Xience or Promus (Limus) vs. paclitaxel-eluting stents (Taxus vs. Costar) in a 1:1:1 ratio 
and stratified according to the presence of diabetes, unprotected let main and in-stent 
restenosis. Primary end-point of the study was target lesion revascularization (TLR) at 
6-months, secondary end-point was the occurrence of major cardiac adverse events 
(MACE) at 6 and 12 months.
Results A total of 359 patients were enrolled: 120 patients received a Limus, 119 a Taxus 
and 120 a Costar stent. No significant difference was reported in clinical characteristics 
among the different groups. At 6 months, TLR was significantly higher in Costar (14.2%) 
as compared to Limus (5.0%, p= 0.028) and showed a trend toward statistical significance 
as compared to Taxus (5.9%, p=0.055). There were no significant differences in rates of 
the other adverse clinical events, including death, MI, TVR, and stent thrombosis. MACE 
at 12 months will presented at the meeting.
Conclusions. This study confirms the high clinical efficacy of DES in daily clinical 
practice. Nevertheless, in a direct comparison, in unselected patients, with Limus and 
Taxus, Costar revealed a lower anti-restenotic efficacy leading to a higher rate of clinically 
driven TLR.
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2806-8 Is Diabetes a Risk Factor for Restenosis and Adverse 
Clinical Outcomes After Paclitaxel-eluting Stent 
Implantation? Pooled Analysis of the TAXUS IV and 
TAXUS V Trials
Gregg W. Stone, Stephen G. Ellis, James B. Hermiller, Jeffrey J. Popma, Neil J. Weissman, 
Lazar Mandinov, Donald S. Baim, Columbia University Medical Center, New York, NY
Background: Diabetes mellitus (DM) is associated with high mortality and increased 
restenosis after PCI. In vitro, paclitaxel inhibits smooth muscle cell proliferation even in 
insulin resistance. The present study examines whether the TAXUS stent is as safe and 
effective in pts with DM as in non DM pts.
Methods: Pts were pooled from the TAXUS IV and TAXUS V de novo randomized trials. 
Angiographic and IVUS outcomes at 9 mos and clinical outcomes at 3 yrs were assessed 
among 317 DM and 862 non DM pts receiving TAXUS stents. Multivariate adjustment was 
performed to correct for baseline differences.
Results: DM pts had more comorbidities and cardiac risk factors than non DM pts. Angiographic 
late loss was comparable and intimal hyperplasia by IVUS was similar for DM and non DM pts 
(Table). At 3 yrs, TLR was similar for DM and non DM pts. MACE and TVR were higher in DM 
vs. non DM pts, driven by increased remote TVR not related to the target lesion; however, there 
were no significant differences in MACE or TVR following adjustment. There were no differences 
in stent thrombosis or cardiac death/MI between DM and non DM pts.
Conclusion: The TAXUS stent mitigates the impact of DM as a risk factor for restenosis 
following PCI, and has a comparable safety and efficacy profile in DM and non DM pts. 
TAXUS IV and TAXUS V de novo patients treated with the TAXUS Express stent 
(N=1179)
Unadjusted Values Adjusted Values
Non-Diabetic 
(N=862)
Diabetic
(N=317)
P-
value
Non-Diabetic
(N=862)
Diabetic
(N=317)
P-
value
In-stent outcomes at 
9 months
Late loss (mm) (QCA) 0.43±0.55 0.44±0.61 0.83 0.42 0.42 0.89
% Diameter stenosis 
(QCA) 19.5±21.5 22.2±23.9 0.12 19.0 21.3 0.17
% Net volume 
obstruction (IVUS) 12.4±12.2 13.9±12.6 0.43 12.3 13.1 0.68
Clinical outcomes at 
3 years Hazard Ratio [95% CI]
MACE 20.0% 27.0% 0.01 1.28 [0.97-1.68] 0.08
- Cardiac death or MI 7.5% 9.5% 0.28 1.16 [0.73-1.84] 0.52
- TVR 16.2% 21.6% 0.035 1.28 [0.95-1.74] 0.11
-- TLR 10.2% 12.2% 0.35 1.11 [0.75-1.66] 0.60
-- TVR remote 7.2% 12.2% 0.009 1.59 [1.04-2.43] 0.03
ST - Protocol 1.4% 1.1% 1.00 0.77 [0.22-2.78] 0.69
ST - ARC Definite/
Probable 2.0% 1.8% 0.80 0.87 [0.32-2.39] 0.79
IVUS=intravascular ultrasound; MACE=major adverse cardiac events (cardiac 
death, MI, TVR); MI=myocardial infarction; PCI=percutaneous coronary intervention; 
QCA=quantitative coronary angiography; ST=stent thrombosis; TVR=target vessel 
revascularization; TLR=target lesion revascularization. Numbers are % (Count/Sample 
Size) or Mean±SD.
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2806-9 Characterization of Target Lesion Revascularization 
After TAXUS Express Paclitaxel-Eluting Stent 
Implantation
Stephen G. Ellis, Antonio Colombo, Eberhard Grube, Gregg W. Stone, Mark Friedman, 
Donald S. Baim, The Cleveland Clinic Foundation, Cleveland, OH
Background: TAXUS paclitaxel-eluting stents (PES) reduce target lesion revascularization 
(TLR) rates compared to bare metal stents. There is no consensus, however, about the 
predictors of TLR in the drug-eluting stent (DES) era, or the long-term outcome of patients 
who develop DES in-stent restenosis. The TAXUS program has more than 1300 patients who 
received PES with up to 5-years of follow-up, allowing these questions to be addressed.
Methods: Patients receiving DES in the TAXUS I (N=31), II-SR (N=131), IV (N=649) and 
V (N=575) studies were included. TLR was defined as a new percutaneous coronary 
intervention (PCI) or coronary artery bypass graft surgery (CABG) involving the originally-
treated target lesion. Only first events were included, and multivariate analysis was performed 
to determine TLR predictors.
Results: The TLR rate was 7.2% at 1 year, increasing to 12.1% at 5 years (1.3%/year 
between 1-5 years). Most (68%) of the TLRs were performed for focal in-stent restenosis, 
with the remainder for diffuse restenosis or total occlusion. TLR was generally via PCI (89%) 
(47% with DES) versus CABG (11%). Predictors of TLR following TAXUS stent insertion 
included the presence of thrombus at initial stenting (HR=2.35), smoking (HR=1.60), and 
total stented length (HR=1.03). Protection against TLR was afforded by prior myocardial 
infarction (HR=0.63) and larger mean stent diameter (HR=0.43). Of a total of 152 TAXUS-
related first TLR events, 25 (16.4%) had an additional intervention an average of 380 days 
after first TLR. Post TLR outcomes included 0.7% death and 1.3% MI at 30 days, and 3.9% 
death and 2.0% MI (2.0% Q-MI, and 0% non-Q MI) at 1 year after TLR.
Conclusions: TAXUS PES demonstrated a durable TLR benefit through 5 years. 
Thrombus, smoking, smaller stent diameter, and total length of stents were independent 
predictors of TLR. Repeat TLR of in-stent restenosis carried favorable subsequent event 
rates compared to those observed in previous analyses.
